<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00544</drugbank-id>
  <drugbank-id>APRD00516</drugbank-id>
  <drugbank-id>EXPT03204</drugbank-id>
  <name>Fluorouracil</name>
  <description>A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.</description>
  <cas-number>51-21-8</cas-number>
  <unii>U3P01618RT</unii>
  <average-mass>130.0772</average-mass>
  <monoisotopic-mass>130.017855555</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A841</ref-id>
        <pubmed-id>12724731</pubmed-id>
        <citation>Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8.</citation>
      </article>
      <article>
        <ref-id>A842</ref-id>
        <pubmed-id>15032669</pubmed-id>
        <citation>Petty RD, Cassidy J: Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets. 2004 Mar;4(2):191-204.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Leroy B. Townsend, Robert A. Earl, Steven J. Manning, "Method of synthesizing 1-(tetrahydro-2-furanyl)-5-fluorouracil." U.S. Patent US3960864, issued October, 1969.</synthesis-reference>
  <indication>For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.</indication>
  <pharmacodynamics>Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the "S" phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand.</pharmacodynamics>
  <mechanism-of-action>The precise mechanism of action has not been fully determined, but the main mechanism of fluorouracil is thought to be the binding of the deoxyribonucleotide of the drug (FdUMP) and the folate cofactor, N5–10-methylenetetrahydrofolate, to thymidylate synthase (TS) to form a covalently bound ternary complex. This results in the inhibition of the formation of thymidylate from uracil, which leads to the inhibition of DNA and RNA synthesis and cell death. Fluorouracil can also be incorporated into RNA in place of uridine triphosphate (UTP), producing a fraudulent RNA and interfering with RNA processing and protein synthesis.</mechanism-of-action>
  <toxicity>LD&lt;sub&gt;50&lt;/sub&gt;=230mg/kg (orally in mice)</toxicity>
  <metabolism>Hepatic. The catabolic metabolism of fluorouracil results in degradation products ( e.g., CO2, urea and α-fluoro-ß-alanine) which are inactive. </metabolism>
  <absorption>28-100%</absorption>
  <half-life>10-20 minutes</half-life>
  <protein-binding>8-12%</protein-binding>
  <route-of-elimination>Seven percent to 20% of the parent drug is excreted unchanged in the urine in 6 hours; of this over 90% is excreted in the first hour.&#13;
The remaining percentage of the administered dose is metabolized, primarily in the liver.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as halopyrimidines. These are aromatic compounds containing a halogen atom linked to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.</description>
    <direct-parent>Halopyrimidines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Diazines</class>
    <subclass>Pyrimidines and pyrimidine derivatives</subclass>
    <alternative-parent>Aryl fluorides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Hydroxypyrimidines</alternative-parent>
    <alternative-parent>Organofluorides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Aryl fluoride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Halopyrimidine</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Hydroxypyrimidine</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organofluoride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="german" coder="">5-Fluoracil</synonym>
    <synonym language="english" coder="">5-Fluoropyrimidine-2,4-dione</synonym>
    <synonym language="english" coder="">5-Fluorouracil</synonym>
    <synonym language="english" coder="">5-Fluracil</synonym>
    <synonym language="english" coder="">5-FU</synonym>
    <synonym language="english" coder="">Fluoro Uracil</synonym>
    <synonym language="english/french" coder="inn/usan">Fluorouracil</synonym>
    <synonym language="spanish" coder="inn">Fluorouracilo</synonym>
    <synonym language="latin" coder="inn">Fluorouracilum</synonym>
    <synonym language="english" coder="">Fluouracil</synonym>
  </synonyms>
  <products>
    <product>
      <name>Actikerall</name>
      <labeller>Cipher Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02428946</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Adrucil</name>
      <labeller>Teva Parenteral Medicines, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0703-3015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA040333</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adrucil</name>
      <labeller>Teva Parenteral Medicines, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0703-3018</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>2.5 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA040334</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adrucil</name>
      <labeller>Teva Parenteral Medicines, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0703-3019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA040334</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Adrucil</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02063921</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2004-04-08</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Adrucil Inj 50mg/ml</name>
      <labeller>Adria Laboratories Of Canada Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00428493</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Carac</name>
      <labeller>Dermik Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0066-7150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-10-27</started-marketing-on>
      <ended-marketing-on>2015-11-30</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>5 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Carac</name>
      <labeller>Bausch Health Americas, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0187-5200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>5 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Efudex</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0951</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-07-29</started-marketing-on>
      <ended-marketing-on>2011-09-30</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>2 g/40g</strength>
      <route>Topical</route>
      <fda-application-number>NDA016831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Efudex</name>
      <labeller>Bausch Health US LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0187-3202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-07-29</started-marketing-on>
      <ended-marketing-on>2008-02-28</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>0.5 g/10mL</strength>
      <route>Topical</route>
      <fda-application-number>NDA016831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Efudex</name>
      <labeller>Bausch Health US LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0187-3203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-07-29</started-marketing-on>
      <ended-marketing-on>2010-01-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>1.25 g/10mL</strength>
      <route>Topical</route>
      <fda-application-number>NDA016831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Efudex</name>
      <labeller>Bausch Health US LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0187-3204</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-07-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>2 g/40g</strength>
      <route>Topical</route>
      <fda-application-number>NDA016831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Efudex Crm 5%</name>
      <labeller>Valeant Canada Lp Valeant Canada S.E.C.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00330582</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1975-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluorac</name>
      <labeller>Burke Therapeutics, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>69101-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-22</started-marketing-on>
      <ended-marketing-on>2015-09-14</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluoroplex</name>
      <labeller>Allergan</labeller>
      <ndc-id/>
      <ndc-product-code>0023-0812</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-03</started-marketing-on>
      <ended-marketing-on>2013-05-01</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>10 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA016988</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluoroplex</name>
      <labeller>Almirall, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>16110-812</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>10 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA016988</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluoroplex Cream 1%</name>
      <labeller>Allergan Herbert Skin Care Division Of Allergan Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01982311</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2011-08-04</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>66758-044</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA040772</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-259</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>NDA016831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-258</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>NDA016831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Oceanside Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68682-085</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2010-01-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>NDA016831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Taro Pharmaceutical Industries, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>52549-4118</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>50 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA090368</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>66758-054</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA091299</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6293</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>50 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA077524</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-829</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-04-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>50 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA077524</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Oceanside Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>68682-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-01</started-marketing-on>
      <ended-marketing-on>2015-01-31</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>5 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA016831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>GeneraMedix</labeller>
      <ndc-id/>
      <ndc-product-code>10139-063</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-08-30</started-marketing-on>
      <ended-marketing-on>2014-06-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA040743</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Spear Dermatology Products</labeller>
      <ndc-id/>
      <ndc-product-code>66530-252</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-23</started-marketing-on>
      <ended-marketing-on>2018-06-20</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>5 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA203122</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0173</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-18</started-marketing-on>
      <ended-marketing-on>2014-11-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA202668</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0169</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-18</started-marketing-on>
      <ended-marketing-on>2014-11-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA202668</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0176</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-18</started-marketing-on>
      <ended-marketing-on>2014-11-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA202669</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0174</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-07-18</started-marketing-on>
      <ended-marketing-on>2014-11-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA202669</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Gland Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>68083-269</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210123</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Gland Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>68083-270</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210123</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Spectrum Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68152-106</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-29</started-marketing-on>
      <ended-marketing-on>2017-09-29</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>2.5 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA012209</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Solubiomix</labeller>
      <ndc-id/>
      <ndc-product-code>69499-326</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-11-05</started-marketing-on>
      <ended-marketing-on>2017-10-10</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>ANDA076526</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Solubiomix</labeller>
      <ndc-id/>
      <ndc-product-code>69499-327</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-11-05</started-marketing-on>
      <ended-marketing-on>2017-10-10</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>ANDA076526</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>16729-276</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA040798</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Sagent Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>25021-215</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA203609</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Blue Point Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>68001-266</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA040798</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Gland Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>68083-292</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Gland Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>68083-293</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA210124</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-4118</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>50 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA090368</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-4062</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-11-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>20 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>ANDA076526</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-4063</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-11-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>ANDA076526</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Spear Dermatology Products Inc</labeller>
      <ndc-id/>
      <ndc-product-code>66530-258</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-28</started-marketing-on>
      <ended-marketing-on>2021-06-20</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>5 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020985</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4264</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>50 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA090368</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Spear Dermatology Products</labeller>
      <ndc-id/>
      <ndc-product-code>66530-249</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-04-11</started-marketing-on>
      <ended-marketing-on>2022-08-31</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>50 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA077524</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-4791</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>5 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA016831</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA040279</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Mayne Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51862-362</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>50 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA077524</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Ingenus Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>50742-482</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>2.5 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA209271</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Ingenus Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>50742-483</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA209271</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Ingenus Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>50742-423</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA209219</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil</name>
      <labeller>Ingenus Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>50742-481</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA209219</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil Cream</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-8078</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>5 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020985</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorouracil Inj 50mg/ml</name>
      <labeller>David Bull Laboratories (Pty) Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00891754</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluorouracil Injection</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00012882</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluorouracil Injection</name>
      <labeller>Biolyse Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473763</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluorouracil Injection</name>
      <labeller>Biolyse Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473771</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluorouracil Injection</name>
      <labeller>Generic Medical Partners Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02476711</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluorouracil Injection</name>
      <labeller>Generic Medical Partners Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02476738</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluorouracil Injection</name>
      <labeller>Generic Medical Partners Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02476746</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluorouracil Injection</name>
      <labeller>Generic Medical Partners Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02476754</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluorouracil Injection USP</name>
      <labeller>Accord Healthcare Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02413450</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluorouracil Injection USP</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02182742</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-11-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tolak</name>
      <labeller>Pierre Fabre Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64370-421</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-15</started-marketing-on>
      <ended-marketing-on>2020-12-31</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>40 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA022259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tolak</name>
      <labeller>Hill Dermaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>28105-421</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>0.04 g/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA022259</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tolak</name>
      <labeller>Hill Dermaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02485346</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>4 %</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Verrunex</name>
      <labeller>Accumix Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>69167-3255</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on>2015-07-17</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Carzonal</name>
      <company>Tobishi</company>
    </international-brand>
    <international-brand>
      <name>Efudix</name>
      <company>Meda</company>
    </international-brand>
    <international-brand>
      <name>Efurix</name>
      <company>Valeant</company>
    </international-brand>
    <international-brand>
      <name>Ftoruracil</name>
      <company>Verofarm</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Efudex</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluoroplex</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Carac</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Verrunex</name>
      <ingredients>Fluorouracil + Salicylic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fluorac</name>
      <ingredients>Diclofenac + Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluoroplex</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil Cream</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Adrucil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Adrucil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Adrucil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Carac</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Tolak</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Tolak</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Efudex</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Efudex</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Efudex</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil Injection</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Efudex Crm 5%</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluoroplex Cream 1%</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil Inj 50mg/ml</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Adrucil</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Adrucil Inj 50mg/ml</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Actikerall</name>
      <ingredients>Fluorouracil + Salicylic acid</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil Injection USP</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil Injection USP</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil Injection</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil Injection</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil Injection</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil Injection</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil Injection</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Fluorouracil Injection</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
    <mixture>
      <name>Tolak</name>
      <ingredients>Fluorouracil</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Allergan Inc.</name>
      <url>http://www.allergan.com</url>
    </packager>
    <packager>
      <name>Amcol Health and Beauty Solutions</name>
      <url>http://www.healthbeautysolutions.com</url>
    </packager>
    <packager>
      <name>APP Pharmaceuticals</name>
      <url>http://www.apppharma.com</url>
    </packager>
    <packager>
      <name>APPD</name>
      <url/>
    </packager>
    <packager>
      <name>Baxter International Inc.</name>
      <url>http://www.baxter.com</url>
    </packager>
    <packager>
      <name>Bigmar Bioren Pharmaceuticals Sa</name>
      <url/>
    </packager>
    <packager>
      <name>Contract Pharm</name>
      <url>http://www.contractpharma.com</url>
    </packager>
    <packager>
      <name>Creative Cosmetics Inc.</name>
      <url>http://www.creativecosmetics.com</url>
    </packager>
    <packager>
      <name>Dermik Labs</name>
      <url/>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Ebewe Pharma</name>
      <url>http://www.ebewe.at</url>
    </packager>
    <packager>
      <name>Generamedix Inc.</name>
      <url>http://www.generamedix.com</url>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Intas Pharmaceuticals Ltd.</name>
      <url>http://www.intaspharma.com</url>
    </packager>
    <packager>
      <name>Legacy Pharmaceuticals Packaging LLC</name>
      <url>http://www.legacypackaging.com</url>
    </packager>
    <packager>
      <name>Medisca Inc.</name>
      <url>http://www.medisca.com</url>
    </packager>
    <packager>
      <name>Oceanside Pharmaceuticals Incorporated</name>
      <url/>
    </packager>
    <packager>
      <name>Pharmacia Inc.</name>
      <url>http://www.pharmaciaupjohn.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Sanofi-Aventis Inc.</name>
      <url>http://www.sanofi-aventis.com</url>
    </packager>
    <packager>
      <name>Sicor Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Solco Healthcare US LLC</name>
      <url>http://www.legacypharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Spear Dermatology Products Inc.</name>
      <url>http://www.spearpharma.com</url>
    </packager>
    <packager>
      <name>Synerx Pharma LLC</name>
      <url>http://www.synerxpharma.com</url>
    </packager>
    <packager>
      <name>Taro Pharmaceuticals USA</name>
      <url>http://www.tarousa.com</url>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
    <packager>
      <name>Valeant Ltd.</name>
      <url>http://www.valeant.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Sanofi aventis us llc</manufacturer>
    <manufacturer generic="false" url="">Valeant pharmaceuticals international</manufacturer>
    <manufacturer generic="false" url="">Allergan herbert skin care div allergan inc</manufacturer>
    <manufacturer generic="true" url="">Spear pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Taro pharmaceutical industries ltd</manufacturer>
    <manufacturer generic="false" url="">Pharmacia and upjohn co</manufacturer>
    <manufacturer generic="false" url="">Teva parenteral medicines inc</manufacturer>
    <manufacturer generic="true" url="">Abic ltd</manufacturer>
    <manufacturer generic="true" url="">Abraxis pharmaceutical products</manufacturer>
    <manufacturer generic="true" url="">App pharmaceuticals llc</manufacturer>
    <manufacturer generic="true" url="">Bedford laboratories div ben venue laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Bioniche pharma usa llc</manufacturer>
    <manufacturer generic="true" url="">Ebewe pharma ges mbh nfg kg</manufacturer>
    <manufacturer generic="true" url="">Marchar laboratories inc ltd</manufacturer>
    <manufacturer generic="true" url="">Smith and nephew solopak div smith and nephew</manufacturer>
    <manufacturer generic="true" url="">Watson laboratories inc</manufacturer>
    <manufacturer generic="false" url="">Elorac inc</manufacturer>
    <manufacturer generic="true" url="">Taro pharmaceuticals usa inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Carac cream</description>
      <cost currency="USD">6.43</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Fluoroplex 1% cream</description>
      <cost currency="USD">7.85</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Fluorouracil powder</description>
      <cost currency="USD">8.45</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Fluorouracil 5% cream</description>
      <cost currency="USD">9.62</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Efudex 5% cream</description>
      <cost currency="USD">10.28</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Fluorouracil 2% Solution 10ml Bottle</description>
      <cost currency="USD">78.63</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Fluorouracil 5% Solution 10ml Bottle</description>
      <cost currency="USD">115.78</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Efudex 5% Solution 10ml Bottle</description>
      <cost currency="USD">136.51</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Carac 0.5% Cream 30 gm Tube</description>
      <cost currency="USD">209.77</cost>
      <unit>tube</unit>
    </price>
    <price>
      <description>Fluorouracil 5% Cream 40 gm Tube</description>
      <cost currency="USD">249.98</cost>
      <unit>tube</unit>
    </price>
    <price>
      <description>Fluoroplex 1% Cream 30 gm Tube</description>
      <cost currency="USD">268.61</cost>
      <unit>tube</unit>
    </price>
    <price>
      <description>Efudex 5% Cream 40 gm Tube</description>
      <cost currency="USD">478.39</cost>
      <unit>tube</unit>
    </price>
    <price>
      <description>Fluorouracil 5000 mg/100 ml</description>
      <cost currency="USD">0.28</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Adrucil 50 mg/ml vial</description>
      <cost currency="USD">0.4</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Fluorouracil 50 mg/ml Solution</description>
      <cost currency="USD">0.52</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Efudex 50 mg/g Cream</description>
      <cost currency="USD">0.9</cost>
      <unit>g</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Antimetabolites</category>
      <mesh-id>D000963</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>BCRP/ABCG2 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cardiotoxic antineoplastic agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2A6 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C8 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C9 Inhibitors</category>
      <mesh-id>D065688</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inhibitors</category>
      <mesh-id>D065607</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Fluoropyrimidines</category>
      <mesh-id/>
    </category>
    <category>
      <category>Fluorouracil and prodrugs</category>
      <mesh-id>D005472</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Immunosuppressive Agents</category>
      <mesh-id>D007166</mesh-id>
    </category>
    <category>
      <category>Misc. Skin and Mucous Membrane Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Moderate Risk QTc-Prolonging Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Myelosuppressive Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Noxae</category>
      <mesh-id>D009676</mesh-id>
    </category>
    <category>
      <category>Nucleic Acid Synthesis Inhibitors</category>
      <mesh-id>D019384</mesh-id>
    </category>
    <category>
      <category>Nucleoside Metabolic Inhibitor</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pyrimidine Analogues</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pyrimidines</category>
      <mesh-id>D011743</mesh-id>
    </category>
    <category>
      <category>Pyrimidinones</category>
      <mesh-id>D011744</mesh-id>
    </category>
    <category>
      <category>QTc Prolonging Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Thyroxine-binding globulin inducers</category>
      <mesh-id/>
    </category>
    <category>
      <category>Toxic Actions</category>
      <mesh-id>D004786</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>2.5 g/50mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>5 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>5 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>2 g/40g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength>0.5 g/10mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength>1.25 g/10mL</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>10 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>50 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>2.5 g/50mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>50 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength>20 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength>50 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>0.04 g/1g</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>4 %</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>40 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Topical</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L01BC52">
      <level code="L01BC">Pyrimidine analogues</level>
      <level code="L01B">ANTIMETABOLITES</level>
      <level code="L01">ANTINEOPLASTIC AGENTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
    <atc-code code="L01BC02">
      <level code="L01BC">Pyrimidine analogues</level>
      <level code="L01B">ANTIMETABOLITES</level>
      <level code="L01">ANTINEOPLASTIC AGENTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>10:00.00</ahfs-code>
    <ahfs-code>84:92.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1h7x</pdb-entry>
    <pdb-entry>1rxc</pdb-entry>
    <pdb-entry>1upf</pdb-entry>
    <pdb-entry>3kvr</pdb-entry>
    <pdb-entry>3kvv</pdb-entry>
    <pdb-entry>3nai</pdb-entry>
    <pdb-entry>3nbq</pdb-entry>
    <pdb-entry>4e1v</pdb-entry>
    <pdb-entry>4o0o</pdb-entry>
    <pdb-entry>4txn</pdb-entry>
    <pdb-entry>4wry</pdb-entry>
    <pdb-entry>4wrz</pdb-entry>
    <pdb-entry>4ws0</pdb-entry>
    <pdb-entry>4ws1</pdb-entry>
    <pdb-entry>5iao</pdb-entry>
    <pdb-entry>5sxc</pdb-entry>
    <pdb-entry>6klk</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00544.pdf?1265922799</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00544.pdf?1265922739</msds>
  <patents>
    <patent>
      <number>6670335</number>
      <country>United States</country>
      <approved>2003-12-30</approved>
      <expires>2021-06-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7169401</number>
      <country>United States</country>
      <approved>2007-01-30</approved>
      <expires>2023-07-18</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Vitamin B1 needs increased with long term use.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06643</drugbank-id>
      <name>Denosumab</name>
      <description>The risk or severity of adverse effects can be increased when Denosumab is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00108</drugbank-id>
      <name>Natalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Natalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00337</drugbank-id>
      <name>Pimecrolimus</name>
      <description>The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>Roflumilast may increase the immunosuppressive activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06688</drugbank-id>
      <name>Sipuleucel-T</name>
      <description>The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09083</drugbank-id>
      <name>Ivabradine</name>
      <description>Ivabradine may increase the QTc-prolonging activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The risk or severity of neutropenia can be increased when Fluorouracil is combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The serum concentration of Fluorouracil can be increased when it is combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The serum concentration of Fluorouracil can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>The serum concentration of Fluorouracil can be decreased when it is combined with Teriflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The serum concentration of Fluorouracil can be increased when it is combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The serum concentration of Fluorouracil can be increased when it is combined with Cimetidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05812</drugbank-id>
      <name>Abiraterone</name>
      <description>The serum concentration of Fluorouracil can be increased when it is combined with Abiraterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The risk or severity of adverse effects can be increased when Leflunomide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08895</drugbank-id>
      <name>Tofacitinib</name>
      <description>Fluorouracil may increase the immunosuppressive activities of Tofacitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the neutropenic activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>Fluorouracil may increase the immunosuppressive activities of Fingolimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>Tacrolimus may increase the immunosuppressive activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Cyproterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>Acetyldigitoxin may decrease the cardiotoxic activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>Deslanoside may decrease the cardiotoxic activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>Ouabain may decrease the cardiotoxic activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>Oleandrin may decrease the cardiotoxic activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13240</drugbank-id>
      <name>Cymarin</name>
      <description>Cymarin may decrease the cardiotoxic activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13307</drugbank-id>
      <name>Proscillaridin</name>
      <description>Proscillaridin may decrease the cardiotoxic activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>Metildigoxin may decrease the cardiotoxic activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>Lanatoside C may decrease the cardiotoxic activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>Gitoformate may decrease the cardiotoxic activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13756</drugbank-id>
      <name>Peruvoside</name>
      <description>Peruvoside may decrease the cardiotoxic activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09257</drugbank-id>
      <name>Gimeracil</name>
      <description>The serum concentration of Fluorouracil can be increased when it is combined with Gimeracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00916</drugbank-id>
      <name>Metronidazole</name>
      <description>The serum concentration of Fluorouracil can be increased when it is combined with Metronidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The risk or severity of adverse effects can be increased when Methotrexate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of bleeding can be increased when Fluorouracil is combined with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of bleeding can be increased when Fluorouracil is combined with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of bleeding can be increased when Fluorouracil is combined with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of bleeding can be increased when Fluorouracil is combined with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of bleeding can be increased when Fluorouracil is combined with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of bleeding can be increased when Fluorouracil is combined with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of bleeding can be increased when Fluorouracil is combined with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00204</drugbank-id>
      <name>Dofetilide</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dofetilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00283</drugbank-id>
      <name>Clemastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Clemastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00308</drugbank-id>
      <name>Ibutilide</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ibutilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Terfenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Sotalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Toremifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Cisapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00637</drugbank-id>
      <name>Astemizole</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Astemizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Trovafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Cocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Procainamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Pimozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Domperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Sparfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01218</drugbank-id>
      <name>Halofantrine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Halofantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Lithium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Temafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04844</drugbank-id>
      <name>Tetrabenazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Tetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Romidepsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Artemether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06708</drugbank-id>
      <name>Lumefantrine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Lumefantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Eliglustat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11730</drugbank-id>
      <name>Ribociclib</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ribociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Glasdegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Deutetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13074</drugbank-id>
      <name>Macimorelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Macimorelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13725</drugbank-id>
      <name>Terodiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Terodiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The risk or severity of QTc prolongation can be increased when Methadone is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Promazine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>The risk or severity of QTc prolongation can be increased when Droperidol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00556</drugbank-id>
      <name>Perflutren</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Perflutren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Cinnarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Atropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00640</drugbank-id>
      <name>Adenosine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Adenosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00743</drugbank-id>
      <name>Gadobenic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Gadobenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00748</drugbank-id>
      <name>Carbinoxamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Carbinoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00757</drugbank-id>
      <name>Dolasetron</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dolasetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00778</drugbank-id>
      <name>Roxithromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Roxithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Nalidixic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Cinoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Loperamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00889</drugbank-id>
      <name>Granisetron</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Granisetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ondansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00922</drugbank-id>
      <name>Levosimendan</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Levosimendan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Mesoridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Fexofenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00976</drugbank-id>
      <name>Telithromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Telithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Lomefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00985</drugbank-id>
      <name>Dimenhydrinate</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dimenhydrinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01113</drugbank-id>
      <name>Papaverine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01114</drugbank-id>
      <name>Chlorpheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Chlorpheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Gemifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Flecainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Clarithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Levacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Clomipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01599</drugbank-id>
      <name>Probucol</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Probucol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Aceprometazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02638</drugbank-id>
      <name>Terlipressin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Terlipressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04825</drugbank-id>
      <name>Prenylamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Prenylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04957</drugbank-id>
      <name>Azimilide</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Azimilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05223</drugbank-id>
      <name>Pracinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Pracinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Garenoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06200</drugbank-id>
      <name>Tedisamil</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Tedisamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06334</drugbank-id>
      <name>Tucidinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Tucidinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06402</drugbank-id>
      <name>Telavancin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Telavancin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Nemonoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08799</drugbank-id>
      <name>Antazoline</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Antazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08903</drugbank-id>
      <name>Bedaquiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Bedaquiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08980</drugbank-id>
      <name>Fendiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Fendiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Eperisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Butriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Melperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Benidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09555</drugbank-id>
      <name>Dexchlorpheniramine maleate</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dexchlorpheniramine maleate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11640</drugbank-id>
      <name>Amifampridine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Amifampridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11830</drugbank-id>
      <name>Mocetinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Mocetinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11841</drugbank-id>
      <name>Entinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Entinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12174</drugbank-id>
      <name>CUDC-101</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with CUDC-101.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12286</drugbank-id>
      <name>Simendan</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Simendan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12376</drugbank-id>
      <name>Ricolinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ricolinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12523</drugbank-id>
      <name>Mizolastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Mizolastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12565</drugbank-id>
      <name>Abexinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Abexinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12877</drugbank-id>
      <name>Oxatomide</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Oxatomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13261</drugbank-id>
      <name>Sitafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Sitafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Sultopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Otilonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13546</drugbank-id>
      <name>Nizofenone</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Nizofenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13652</drugbank-id>
      <name>Bunaftine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Bunaftine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13653</drugbank-id>
      <name>Lorcainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Lorcainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13679</drugbank-id>
      <name>Dexchlorpheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dexchlorpheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dexverapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ivosidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00107</drugbank-id>
      <name>Oxytocin</name>
      <description>The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Esmolol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Isradipine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Buclizine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Timolol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The risk or severity of QTc prolongation can be increased when Digoxin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00405</drugbank-id>
      <name>Dexbrompheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00427</drugbank-id>
      <name>Triprolidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00529</drugbank-id>
      <name>Foscarnet</name>
      <description>The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00557</drugbank-id>
      <name>Hydroxyzine</name>
      <description>The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00613</drugbank-id>
      <name>Amodiaquine</name>
      <description>The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Galantamine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Moricizine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>The risk or severity of QTc prolongation can be increased when Moexipril is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00719</drugbank-id>
      <name>Azatadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Azatadine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Risperidone is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The risk or severity of QTc prolongation can be increased when Indapamide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The risk or severity of QTc prolongation can be increased when Propofol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00822</drugbank-id>
      <name>Disulfiram</name>
      <description>The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00825</drugbank-id>
      <name>Levomenthol</name>
      <description>The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Amantadine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00920</drugbank-id>
      <name>Ketotifen</name>
      <description>The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Famotidine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The risk or severity of QTc prolongation can be increased when Felbamate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Formoterol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Promethazine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01071</drugbank-id>
      <name>Mequitazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01106</drugbank-id>
      <name>Levocabastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Desipramine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01158</drugbank-id>
      <name>Bretylium</name>
      <description>The risk or severity of QTc prolongation can be increased when Bretylium is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01176</drugbank-id>
      <name>Cyclizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>The risk or severity of QTc prolongation can be increased when Desflurane is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01228</drugbank-id>
      <name>Encainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Encainide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01426</drugbank-id>
      <name>Ajmaline</name>
      <description>The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01620</drugbank-id>
      <name>Pheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04695</drugbank-id>
      <name>Farnesyl thiopyrophosphate</name>
      <description>The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05465</drugbank-id>
      <name>Tandutinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06217</drugbank-id>
      <name>Vernakalant</name>
      <description>The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>The risk or severity of QTc prolongation can be increased when Ziconotide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06468</drugbank-id>
      <name>Cariporide</name>
      <description>The risk or severity of QTc prolongation can be increased when Cariporide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06663</drugbank-id>
      <name>Pasireotide</name>
      <description>The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06691</drugbank-id>
      <name>Mepyramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06699</drugbank-id>
      <name>Degarelix</name>
      <description>The risk or severity of QTc prolongation can be increased when Degarelix is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06719</drugbank-id>
      <name>Buserelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Buserelin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06788</drugbank-id>
      <name>Histrelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Histrelin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06825</drugbank-id>
      <name>Triptorelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07780</drugbank-id>
      <name>Farnesyl diphosphate</name>
      <description>The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07841</drugbank-id>
      <name>Geranylgeranyl diphosphate</name>
      <description>The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08936</drugbank-id>
      <name>Chlorcyclizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Indenolol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>The risk or severity of QTc prolongation can be increased when Flumequine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09090</drugbank-id>
      <name>Pinaverium</name>
      <description>The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09229</drugbank-id>
      <name>Aranidipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aranidipine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Efonidipine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Niguldipine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09488</drugbank-id>
      <name>Acrivastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11390</drugbank-id>
      <name>Coumaphos</name>
      <description>The risk or severity of QTc prolongation can be increased when Coumaphos is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11397</drugbank-id>
      <name>Dichlorvos</name>
      <description>The risk or severity of QTc prolongation can be increased when Dichlorvos is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11408</drugbank-id>
      <name>Famphur</name>
      <description>The risk or severity of QTc prolongation can be increased when Famphur is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11412</drugbank-id>
      <name>Fenthion</name>
      <description>The risk or severity of QTc prolongation can be increased when Fenthion is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11443</drugbank-id>
      <name>Orbifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11448</drugbank-id>
      <name>Phosmet</name>
      <description>The risk or severity of QTc prolongation can be increased when Phosmet is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11491</drugbank-id>
      <name>Sarafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11511</drugbank-id>
      <name>Difloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Difloxacin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11591</drugbank-id>
      <name>Bilastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Bilastine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11614</drugbank-id>
      <name>Rupatadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11742</drugbank-id>
      <name>Ebastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Ebastine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Talinolol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Anisodamine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11891</drugbank-id>
      <name>CUDC-907</name>
      <description>The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tetrahydropalmatine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12231</drugbank-id>
      <name>Temefos</name>
      <description>The risk or severity of QTc prolongation can be increased when Temefos is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12245</drugbank-id>
      <name>Triclabendazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12645</drugbank-id>
      <name>Givinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Givinostat is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12712</drugbank-id>
      <name>Pilsicainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13358</drugbank-id>
      <name>Cibenzoline</name>
      <description>The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13488</drugbank-id>
      <name>Bencyclane</name>
      <description>The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13555</drugbank-id>
      <name>Prajmaline</name>
      <description>The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13651</drugbank-id>
      <name>Lorajmine</name>
      <description>The risk or severity of QTc prolongation can be increased when Lorajmine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13744</drugbank-id>
      <name>Piromidic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13766</drugbank-id>
      <name>Lidoflazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13772</drugbank-id>
      <name>Rufloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13823</drugbank-id>
      <name>Pipemidic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14713</drugbank-id>
      <name>Inotersen</name>
      <description>The risk or severity of QTc prolongation can be increased when Inotersen is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The metabolism of Primidone can be increased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00201</drugbank-id>
      <name>Caffeine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Caffeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Moxifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Lidocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00379</drugbank-id>
      <name>Mexiletine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Mexiletine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Imipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00969</drugbank-id>
      <name>Alosetron</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Alosetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Gatifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Lobeglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Curcumin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Pazufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Secobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Rifampicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Phenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Lovastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Diltiazem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Amlodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Rosiglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Trimethoprim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Loratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Nabilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Efavirenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Tamoxifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Irbesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Oxybutynin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Fluvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Pioglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00549</drugbank-id>
      <name>Zafirlukast</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Zafirlukast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Clopidogrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Candesartan cilexetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Salmeterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Felodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Gemfibrozil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08911</drugbank-id>
      <name>Trametinib</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Trametinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Dabrafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01217</drugbank-id>
      <name>Anastrozole</name>
      <description>The risk or severity of cardiotoxicity can be increased when Fluorouracil is combined with Anastrozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06013</drugbank-id>
      <name>Aldoxorubicin</name>
      <description>The risk or severity of cardiotoxicity can be increased when Fluorouracil is combined with Aldoxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06171</drugbank-id>
      <name>Paclitaxel trevatide</name>
      <description>The risk or severity of cardiotoxicity can be increased when Fluorouracil is combined with Paclitaxel trevatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13809</drugbank-id>
      <name>Paclitaxel poliglumex</name>
      <description>The risk or severity of cardiotoxicity can be increased when Fluorouracil is combined with Paclitaxel poliglumex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The serum concentration of Fluorouracil can be decreased when it is combined with Osimertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The therapeutic efficacy of G17DT can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05144</drugbank-id>
      <name>PEV3A</name>
      <description>The therapeutic efficacy of PEV3A can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The therapeutic efficacy of INGN 225 can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The therapeutic efficacy of SRP 299 can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The therapeutic efficacy of GI-5005 can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06400</drugbank-id>
      <name>Vitespen</name>
      <description>The therapeutic efficacy of Vitespen can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The therapeutic efficacy of TG4010 can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09057</drugbank-id>
      <name>Anthrax immune globulin human</name>
      <description>The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10062</drugbank-id>
      <name>Rabies virus inactivated antigen, B</name>
      <description>The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10076</drugbank-id>
      <name>Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10276</drugbank-id>
      <name>Rotavirus vaccine</name>
      <description>The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10342</drugbank-id>
      <name>Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10583</drugbank-id>
      <name>Clostridium tetani toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10584</drugbank-id>
      <name>Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10600</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10769</drugbank-id>
      <name>Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10794</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10803</drugbank-id>
      <name>Typhoid Vi polysaccharide vaccine</name>
      <description>The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10989</drugbank-id>
      <name>Hepatitis A Vaccine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10990</drugbank-id>
      <name>Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11038</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11040</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11041</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11044</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11603</drugbank-id>
      <name>Human rabies virus immune globulin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11627</drugbank-id>
      <name>Hepatitis B Vaccine (Recombinant)</name>
      <description>The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12568</drugbank-id>
      <name>Tecemotide</name>
      <description>The therapeutic efficacy of Tecemotide can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14384</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14385</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14394</drugbank-id>
      <name>Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14445</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14449</drugbank-id>
      <name>Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen</name>
      <description>The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14619</drugbank-id>
      <name>Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14620</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14711</drugbank-id>
      <name>Vaccinia virus strain new york city board of health live antigen</name>
      <description>The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15274</drugbank-id>
      <name>Pertussis vaccine</name>
      <description>The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15461</drugbank-id>
      <name>Yersinia pestis 195/p antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13924</drugbank-id>
      <name>Varicella Zoster Vaccine (Recombinant)</name>
      <description>The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15483</drugbank-id>
      <name>Modified vaccinia ankara</name>
      <description>The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The risk or severity of bleeding can be increased when Abciximab is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>The risk or severity of bleeding can be increased when Eptifibatide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>The risk or severity of bleeding can be increased when Tirofiban is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The risk or severity of bleeding can be increased when Dipyridamole is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of bleeding can be increased when Iloprost is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>The risk or severity of bleeding can be increased when Ridogrel is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The risk or severity of bleeding can be increased when Epoprostenol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of bleeding can be increased when Nimesulide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The risk or severity of bleeding can be increased when Tesmilifene is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>The risk or severity of bleeding can be increased when Defibrotide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>The risk or severity of bleeding can be increased when Ibudilast is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>Andrographolide</name>
      <description>The risk or severity of bleeding can be increased when Andrographolide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>Caplacizumab</name>
      <description>The risk or severity of bleeding can be increased when Caplacizumab is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>The risk or severity of bleeding can be increased when Cangrelor is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>The risk or severity of bleeding can be increased when Triflusal is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The risk or severity of bleeding can be increased when Ticagrelor is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The risk or severity of bleeding can be increased when Vorapaxar is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>The risk or severity of bleeding can be increased when Trapidil is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of bleeding can be increased when Naftopidil is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12163</drugbank-id>
      <name>Sarpogrelate</name>
      <description>The risk or severity of bleeding can be increased when Sarpogrelate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12321</drugbank-id>
      <name>Ifetroban</name>
      <description>The risk or severity of bleeding can be increased when Ifetroban is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of bleeding can be increased when Nitroaspirin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>The risk or severity of bleeding can be increased when Ketanserin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of bleeding can be increased when Indobufen is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>The risk or severity of bleeding can be increased when Butylphthalide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12771</drugbank-id>
      <name>Hydroxytyrosol</name>
      <description>The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>The risk or severity of bleeding can be increased when Ramatroban is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13327</drugbank-id>
      <name>Picotamide</name>
      <description>The risk or severity of bleeding can be increased when Picotamide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13367</drugbank-id>
      <name>Cloricromen</name>
      <description>The risk or severity of bleeding can be increased when Cloricromen is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>The risk or severity of bleeding can be increased when Linsidomine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>The risk or severity of bleeding can be increased when Buflomedil is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13929</drugbank-id>
      <name>Relcovaptan</name>
      <description>The risk or severity of bleeding can be increased when Relcovaptan is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The serum concentration of Fluorouracil can be increased when it is combined with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11988</drugbank-id>
      <name>Ocrelizumab</name>
      <description>Ocrelizumab may increase the immunosuppressive activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11637</drugbank-id>
      <name>Delamanid</name>
      <description>Fluorouracil may increase the QTc-prolonging activities of Delamanid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13200</drugbank-id>
      <name>Lipegfilgrastim</name>
      <description>Fluorouracil may increase the myelosuppressive activities of Lipegfilgrastim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10317</drugbank-id>
      <name>Rubella virus vaccine</name>
      <description>The risk or severity of infection can be increased when Rubella virus vaccine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10318</drugbank-id>
      <name>Varicella Zoster Vaccine (Live/attenuated)</name>
      <description>The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10343</drugbank-id>
      <name>Bacillus calmette-guerin substrain tice live antigen</name>
      <description>The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10804</drugbank-id>
      <name>Bacillus calmette-guerin substrain connaught live antigen</name>
      <description>The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10805</drugbank-id>
      <name>Yellow Fever Vaccine</name>
      <description>The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11003</drugbank-id>
      <name>Anthrax vaccine</name>
      <description>The risk or severity of infection can be increased when Anthrax vaccine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11050</drugbank-id>
      <name>Typhoid Vaccine Live</name>
      <description>The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12386</drugbank-id>
      <name>Bacillus calmette-guerin substrain danish 1331 live antigen</name>
      <description>The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The risk or severity of infection can be increased when BCG vaccine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14409</drugbank-id>
      <name>Human adenovirus e serotype 4 strain cl-68578 antigen</name>
      <description>The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14443</drugbank-id>
      <name>Vibrio cholerae CVD 103-HgR strain live antigen</name>
      <description>The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14685</drugbank-id>
      <name>Adenovirus type 7 vaccine live</name>
      <description>The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00039</drugbank-id>
      <name>Palifermin</name>
      <description>The therapeutic efficacy of Palifermin can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Cerivastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00471</drugbank-id>
      <name>Montelukast</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Montelukast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00481</drugbank-id>
      <name>Raloxifene</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Raloxifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Piroxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Simvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00665</drugbank-id>
      <name>Nilutamide</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Nilutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Phenelzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Meloxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Sulfinpyrazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01393</drugbank-id>
      <name>Bezafibrate</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Bezafibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01698</drugbank-id>
      <name>Rutin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Rutin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Licofelone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06729</drugbank-id>
      <name>Sulfaphenazole</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Sulfaphenazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09280</drugbank-id>
      <name>Lumacaftor</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Lumacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11632</drugbank-id>
      <name>Opicapone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Opicapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12015</drugbank-id>
      <name>Alpelisib</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Alpelisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Candesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Mefenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00615</drugbank-id>
      <name>Rifabutin</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Rifabutin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Nicotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Torasemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00250</drugbank-id>
      <name>Dapsone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Dapsone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Theophylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Morphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Sulfadiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Eszopiclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The metabolism of Diclofenac can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>The metabolism of Paramethadione can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The metabolism of Naproxen can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00799</drugbank-id>
      <name>Tazarotene</name>
      <description>The metabolism of Tazarotene can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The metabolism of Terbinafine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The metabolism of Repaglinide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The metabolism of Almotriptan can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The metabolism of Selegiline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The metabolism of Ibuprofen can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The metabolism of Atorvastatin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The metabolism of Tolbutamide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>The metabolism of Zopiclone can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The metabolism of Ketamine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The metabolism of Sitagliptin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The metabolism of Mestranol can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The metabolism of Aminophenazone can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The metabolism of Antipyrine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The metabolism of Beraprost can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06510</drugbank-id>
      <name>Muraglitazar</name>
      <description>The metabolism of Muraglitazar can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The metabolism of Apixaban can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06670</drugbank-id>
      <name>Odanacatib</name>
      <description>The metabolism of Odanacatib can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The metabolism of Ketobemidone can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>The metabolism of Seratrodast can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The metabolism of Benzyl alcohol can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The metabolism of (R)-warfarin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>The metabolism of Pitavastatin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The metabolism of Levomilnacipran can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The metabolism of Perospirone can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>The metabolism of Riociguat can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The metabolism of Vortioxetine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>The metabolism of Netoglitazone can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>The metabolism of Rivoglitazone can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The metabolism of Ciglitazone can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The metabolism of Tegafur can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The metabolism of Propacetamol can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09296</drugbank-id>
      <name>Ombitasvir</name>
      <description>The metabolism of Ombitasvir can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>The metabolism of Ixazomib can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The metabolism of Selexipag can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The metabolism of Apalutamide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11979</drugbank-id>
      <name>Elagolix</name>
      <description>The metabolism of Elagolix can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12130</drugbank-id>
      <name>Lorlatinib</name>
      <description>The metabolism of Lorlatinib can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The metabolism of Balaglitazone can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>The metabolism of Testosterone cypionate can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>The metabolism of Testosterone enanthate can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>The metabolism of Testosterone undecanoate can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The metabolism of (S)-Warfarin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The metabolism of Istradefylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The metabolism of Azelastine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The metabolism of Dexibuprofen can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Ketorolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08502</drugbank-id>
      <name>Capravirine</name>
      <description>The metabolism of Capravirine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The metabolism of Phenytoin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The metabolism of Phenprocoumon can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The metabolism of Amiodarone can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The metabolism of Paclitaxel can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The metabolism of Fosphenytoin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00060</drugbank-id>
      <name>Interferon beta-1a</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Interferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Ticlopidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Nitric Oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00553</drugbank-id>
      <name>Methoxsalen</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Methoxsalen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Dexmedetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00730</drugbank-id>
      <name>Thiabendazole</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Thiabendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Tegaserod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Resveratrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Estrone sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05396</drugbank-id>
      <name>Albinterferon Alfa-2B</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Albinterferon Alfa-2B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05990</drugbank-id>
      <name>Obeticholic acid</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Obeticholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Dapagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06803</drugbank-id>
      <name>Niclosamide</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Niclosamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Stiripentol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11198</drugbank-id>
      <name>Peppermint oil</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Peppermint oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11404</drugbank-id>
      <name>Enrofloxacin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Enrofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11994</drugbank-id>
      <name>Diacerein</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Diacerein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Dihydralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13174</drugbank-id>
      <name>Rhein</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Rhein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13975</drugbank-id>
      <name>Black cohosh</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Black cohosh.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14999</drugbank-id>
      <name>Human interferon beta</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Human interferon beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15119</drugbank-id>
      <name>Ropeginterferon alfa-2b</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Ropeginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15131</drugbank-id>
      <name>Interferon alfa-2c</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Interferon alfa-2c.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Isoniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06442</drugbank-id>
      <name>Avasimibe</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Avasimibe.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14635</drugbank-id>
      <name>Curcumin sulfate</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Curcumin sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Conjugated estrogens.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Ropivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Zolmitriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Acetaminophen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Chlorzoxazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Tacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Triamterene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Zolpidem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00442</drugbank-id>
      <name>Entecavir</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Entecavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Nabumetone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Flutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Albendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The metabolism of Clonidine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The metabolism of Guanabenz can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The metabolism of Riluzole can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>The metabolism of Zileuton can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>The metabolism of Acyclovir can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The metabolism of Pentoxifylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The metabolism of Trifluoperazine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The metabolism of Ranitidine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The metabolism of Ethanol can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The metabolism of Cyclobenzaprine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The metabolism of Ramelteon can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The metabolism of Frovatriptan can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>The metabolism of Levobupivacaine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01012</drugbank-id>
      <name>Cinacalcet</name>
      <description>The metabolism of Cinacalcet can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01056</drugbank-id>
      <name>Tocainide</name>
      <description>The metabolism of Tocainide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01058</drugbank-id>
      <name>Praziquantel</name>
      <description>The metabolism of Praziquantel can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The metabolism of Melatonin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The metabolism of Carvedilol can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01191</drugbank-id>
      <name>Dexfenfluramine</name>
      <description>The metabolism of Dexfenfluramine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Aminophylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01303</drugbank-id>
      <name>Oxtriphylline</name>
      <description>The metabolism of Oxtriphylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The metabolism of Rasagiline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>The metabolism of Theobromine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01482</drugbank-id>
      <name>Fenethylline</name>
      <description>The metabolism of Fenethylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>The metabolism of Bromazepam can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The metabolism of Etoricoxib can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01667</drugbank-id>
      <name>8-azaguanine</name>
      <description>The metabolism of 8-azaguanine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02134</drugbank-id>
      <name>Xanthine</name>
      <description>The metabolism of Xanthine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02489</drugbank-id>
      <name>9-Methylguanine</name>
      <description>The metabolism of 9-Methylguanine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02568</drugbank-id>
      <name>Peldesine</name>
      <description>The metabolism of Peldesine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03783</drugbank-id>
      <name>Phenacetin</name>
      <description>The metabolism of Phenacetin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04076</drugbank-id>
      <name>Hypoxanthine</name>
      <description>The metabolism of Hypoxanthine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04356</drugbank-id>
      <name>9-Deazaguanine</name>
      <description>The metabolism of 9-Deazaguanine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The metabolism of Flunarizine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>The metabolism of Lorcaserin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The metabolism of Lofexidine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The metabolism of Mianserin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06235</drugbank-id>
      <name>Vadimezan</name>
      <description>The metabolism of Vadimezan can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06479</drugbank-id>
      <name>Propentofylline</name>
      <description>The metabolism of Propentofylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06594</drugbank-id>
      <name>Agomelatine</name>
      <description>The metabolism of Agomelatine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The metabolism of Axitinib can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06774</drugbank-id>
      <name>Capsaicin</name>
      <description>The metabolism of Capsaicin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>The metabolism of Perampanel can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>The metabolism of Tasimelteon can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>The metabolism of Zotepine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The metabolism of Doxofylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09290</drugbank-id>
      <name>Ramosetron</name>
      <description>The metabolism of Ramosetron can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11919</drugbank-id>
      <name>6-O-benzylguanine</name>
      <description>The metabolism of 6-O-benzylguanine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11967</drugbank-id>
      <name>Binimetinib</name>
      <description>The metabolism of Binimetinib can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>The metabolism of Lisofylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12531</drugbank-id>
      <name>Lobucavir</name>
      <description>The metabolism of Lobucavir can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12926</drugbank-id>
      <name>Cafedrine</name>
      <description>The metabolism of Cafedrine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12927</drugbank-id>
      <name>Theodrenaline</name>
      <description>The metabolism of Theodrenaline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13203</drugbank-id>
      <name>Bamifylline</name>
      <description>The metabolism of Bamifylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13449</drugbank-id>
      <name>Proxyphylline</name>
      <description>The metabolism of Proxyphylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13573</drugbank-id>
      <name>Acefylline</name>
      <description>The metabolism of Acefylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13592</drugbank-id>
      <name>Etamiphylline</name>
      <description>The metabolism of Etamiphylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13634</drugbank-id>
      <name>Pentifylline</name>
      <description>The metabolism of Pentifylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13812</drugbank-id>
      <name>Bufylline</name>
      <description>The metabolism of Bufylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>The metabolism of Bromotheophylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14132</drugbank-id>
      <name>8-chlorotheophylline</name>
      <description>The metabolism of 8-chlorotheophylline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The metabolism of Perphenazine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The metabolism of Paroxetine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04889</drugbank-id>
      <name>Bicifadine</name>
      <description>The metabolism of Bicifadine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05708</drugbank-id>
      <name>GTS-21</name>
      <description>The metabolism of GTS-21 can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Enoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Rofecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05488</drugbank-id>
      <name>Technetium Tc-99m ciprofloxacin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Technetium Tc-99m ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14025</drugbank-id>
      <name>Clinafloxacin</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Clinafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14029</drugbank-id>
      <name>Furafylline</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Furafylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>The risk or severity of bleeding can be increased when Bivalirudin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>The risk or severity of bleeding can be increased when Alteplase is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>The risk or severity of bleeding can be increased when Urokinase is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>The risk or severity of bleeding can be increased when Reteplase is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>The risk or severity of bleeding can be increased when Anistreplase is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>The risk or severity of bleeding can be increased when Tenecteplase is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The risk or severity of bleeding can be increased when Streptokinase is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The risk or severity of bleeding can be increased when Argatroban is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The risk or severity of bleeding can be increased when Ardeparin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>The risk or severity of bleeding can be increased when Fondaparinux is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan polysulfate</name>
      <description>The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The risk or severity of bleeding can be increased when Enoxaparin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>The risk or severity of bleeding can be increased when Desmoteplase is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>The risk or severity of bleeding can be increased when Ancrod is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>The risk or severity of bleeding can be increased when Fibrinolysin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The risk or severity of bleeding can be increased when Rivaroxaban is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The risk or severity of bleeding can be increased when Sulodexide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>The risk or severity of bleeding can be increased when Semuloparin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>The risk or severity of bleeding can be increased when Idraparinux is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>The risk or severity of bleeding can be increased when Astaxanthin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>The risk or severity of bleeding can be increased when Otamixaban is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>The risk or severity of bleeding can be increased when Amediplase is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The risk or severity of bleeding can be increased when Danaparoid is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The risk or severity of bleeding can be increased when Dalteparin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The risk or severity of bleeding can be increased when Tinzaparin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The risk or severity of bleeding can be increased when Ferulic acid is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The risk or severity of bleeding can be increased when Nadroparin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>The risk or severity of bleeding can be increased when Ditazole is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The risk or severity of bleeding can be increased when Edoxaban is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>The risk or severity of bleeding can be increased when Potassium citrate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>The risk or severity of bleeding can be increased when Sodium citrate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>The risk or severity of bleeding can be increased when Dextran is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The risk or severity of bleeding can be increased when Bemiparin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The risk or severity of bleeding can be increased when Reviparin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The risk or severity of bleeding can be increased when Parnaparin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>The risk or severity of bleeding can be increased when Certoparin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>The risk or severity of bleeding can be increased when Desirudin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>The risk or severity of bleeding can be increased when Zinc citrate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11166</drugbank-id>
      <name>Antithrombin Alfa</name>
      <description>The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>The risk or severity of bleeding can be increased when Protein C is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>The risk or severity of bleeding can be increased when Antithrombin III human is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>The risk or severity of bleeding can be increased when Letaxaban is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>The risk or severity of bleeding can be increased when Darexaban is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The risk or severity of bleeding can be increased when Betrixaban is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>The risk or severity of bleeding can be increased when Nafamostat is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>The risk or severity of bleeding can be increased when Monteplase is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>The risk or severity of bleeding can be increased when Gabexate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>The risk or severity of bleeding can be increased when Protein S human is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>The risk or severity of bleeding can be increased when Brinase is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>The risk or severity of bleeding can be increased when Melagatran is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>The risk or severity of bleeding can be increased when Saruplase is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14598</drugbank-id>
      <name>Edetate calcium disodium anhydrous</name>
      <description>The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14600</drugbank-id>
      <name>Edetate disodium anhydrous</name>
      <description>The risk or severity of bleeding can be increased when Edetate disodium anhydrous is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14726</drugbank-id>
      <name>Dabigatran</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Troglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>The metabolism of Valsartan can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The metabolism of Sildenafil can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The metabolism of Glimepiride can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The metabolism of Desogestrel can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The metabolism of Hydromorphone can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The metabolism of Alprazolam can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The metabolism of Acetohexamide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The metabolism of Tenoxicam can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>The metabolism of Bosentan can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The metabolism of Valdecoxib can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The metabolism of Doxazosin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The metabolism of Chlorpropamide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The metabolism of Flurbiprofen can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The metabolism of Nateglinide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The metabolism of Etodolac can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The metabolism of Phenylbutazone can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The metabolism of Tolazamide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The metabolism of Salicylic acid can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The metabolism of Acetylsalicylic acid can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The metabolism of Glyburide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The metabolism of Glipizide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The metabolism of Rosuvastatin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The metabolism of Gliclazide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01131</drugbank-id>
      <name>Proguanil</name>
      <description>The metabolism of Proguanil can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The metabolism of Thiamylal can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>The metabolism of Moclobemide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The metabolism of Gliquidone can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The metabolism of Lumiracoxib can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The metabolism of Glisoxepide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The metabolism of Hexobarbital can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01589</drugbank-id>
      <name>Quazepam</name>
      <description>The metabolism of Quazepam can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03756</drugbank-id>
      <name>Doconexent</name>
      <description>The metabolism of Doconexent can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04557</drugbank-id>
      <name>Arachidonic Acid</name>
      <description>The metabolism of Arachidonic Acid can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>The metabolism of Ximelagatran can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04938</drugbank-id>
      <name>Ospemifene</name>
      <description>The metabolism of Ospemifene can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>The metabolism of Brivaracetam can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>The metabolism of Tapentadol can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>The metabolism of Prasugrel can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>The metabolism of Lacosamide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06268</drugbank-id>
      <name>Sitaxentan</name>
      <description>The metabolism of Sitaxentan can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>The metabolism of Indisulam can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06414</drugbank-id>
      <name>Etravirine</name>
      <description>The metabolism of Etravirine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06652</drugbank-id>
      <name>Vicriviroc</name>
      <description>The metabolism of Vicriviroc can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The metabolism of Lornoxicam can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The metabolism of Zaltoprofen can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The metabolism of Tranilast can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The metabolism of Parecoxib can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08875</drugbank-id>
      <name>Cabozantinib</name>
      <description>The metabolism of Cabozantinib can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The metabolism of Glibornuride can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09048</drugbank-id>
      <name>Netupitant</name>
      <description>The metabolism of Netupitant can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11560</drugbank-id>
      <name>Lesinurad</name>
      <description>The metabolism of Lesinurad can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>The metabolism of Esketamine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The metabolism of Erdafitinib can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>The metabolism of Lynestrenol can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The metabolism of Carbutamide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The metabolism of Metahexamide can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13941</drugbank-id>
      <name>Piperaquine</name>
      <description>The metabolism of Piperaquine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The metabolism of Diazepam can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The metabolism of Donepezil can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The metabolism of Dextromethorphan can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>The metabolism of Testosterone can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The metabolism of Losartan can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>The metabolism of Amprenavir can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14975</drugbank-id>
      <name>Voxelotor</name>
      <description>The metabolism of Voxelotor can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The metabolism of Bupropion can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The metabolism of Sertraline can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The metabolism of Dicoumarol can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The metabolism of Valproic acid can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The metabolism of Quinidine can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The metabolism of Doxepin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The metabolism of Acenocoumarol can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>The metabolism of Siponimod can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The metabolism of Fluindione can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Diazoxide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00116</drugbank-id>
      <name>Tetrahydrofolic acid</name>
      <description>The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic acid</name>
      <description>The risk or severity of adverse effects can be increased when Folic acid is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00650</drugbank-id>
      <name>Leucovorin</name>
      <description>The risk or severity of adverse effects can be increased when Leucovorin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02031</drugbank-id>
      <name>(6S)-5,6,7,8-tetrahydrofolic acid</name>
      <description>The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02067</drugbank-id>
      <name>Triglu-5-formyl-tetrahydrofolate</name>
      <description>The risk or severity of adverse effects can be increased when Triglu-5-formyl-tetrahydrofolate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03256</drugbank-id>
      <name>(6R)-Folinic acid</name>
      <description>The risk or severity of adverse effects can be increased when (6R)-Folinic acid is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04789</drugbank-id>
      <name>5-methyltetrahydrofolic acid</name>
      <description>The risk or severity of adverse effects can be increased when 5-methyltetrahydrofolic acid is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11256</drugbank-id>
      <name>Levomefolic acid</name>
      <description>The risk or severity of adverse effects can be increased when Levomefolic acid is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11596</drugbank-id>
      <name>Levoleucovorin</name>
      <description>The risk or severity of adverse effects can be increased when Levoleucovorin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Adalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Infliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Afelimomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Fluorouracil may increase the immunosuppressive activities of Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00115</drugbank-id>
      <name>Cyanocobalamin</name>
      <description>The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The therapeutic efficacy of Furosemide can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>The therapeutic efficacy of Nitrofurantoin can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>The therapeutic efficacy of Ethotoin can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The therapeutic efficacy of Meclofenamic acid can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The therapeutic efficacy of Heparin can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>The therapeutic efficacy of Dantrolene can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The therapeutic efficacy of Etofenamate can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12425</drugbank-id>
      <name>Liothyronine I-131</name>
      <description>The therapeutic efficacy of Liothyronine I-131 can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13396</drugbank-id>
      <name>Neocitrullamon</name>
      <description>The therapeutic efficacy of Neocitrullamon can be decreased when used in combination with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The therapeutic efficacy of Fluorouracil can be decreased when used in combination with Levothyroxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>The therapeutic efficacy of Fluorouracil can be decreased when used in combination with Enzalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>The therapeutic efficacy of Fluorouracil can be decreased when used in combination with Liotrix.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The therapeutic efficacy of Fluorouracil can be decreased when used in combination with Mephenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>The risk or severity of adverse effects can be increased when Allopurinol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The risk or severity of QTc prolongation can be increased when Trazodone is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Entrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>Fluorouracil may increase the QTc-prolonging activities of Pitolisant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12825</drugbank-id>
      <name>Lefamulin</name>
      <description>Lefamulin may increase the QTc-prolonging activities of Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15066</drugbank-id>
      <name>Givosiran</name>
      <description>The serum concentration of Fluorouracil can be increased when it is combined with Givosiran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The serum concentration of Fluorouracil can be increased when it is combined with Gemcitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00400</drugbank-id>
      <name>Griseofulvin</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Griseofulvin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01201</drugbank-id>
      <name>Rifapentine</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Rifapentine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01220</drugbank-id>
      <name>Rifaximin</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Rifaximin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Rifamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14542</drugbank-id>
      <name>Hydrocortisone phosphate</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Hydrocortisone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00011</drugbank-id>
      <name>Interferon alfa-n1</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00018</drugbank-id>
      <name>Interferon alfa-n3</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00033</drugbank-id>
      <name>Interferon gamma-1b</name>
      <description>The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00034</drugbank-id>
      <name>Interferon alfa-2a, Recombinant</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00068</drugbank-id>
      <name>Interferon beta-1b</name>
      <description>The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00069</drugbank-id>
      <name>Interferon alfacon-1</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The risk or severity of adverse effects can be increased when Rituximab is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00074</drugbank-id>
      <name>Basiliximab</name>
      <description>The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00075</drugbank-id>
      <name>Muromonab</name>
      <description>The risk or severity of adverse effects can be increased when Muromonab is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00092</drugbank-id>
      <name>Alefacept</name>
      <description>The risk or severity of adverse effects can be increased when Alefacept is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00095</drugbank-id>
      <name>Efalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00098</drugbank-id>
      <name>Antithymocyte immunoglobulin (rabbit)</name>
      <description>The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon alfa-2b</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00111</drugbank-id>
      <name>Daclizumab</name>
      <description>The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00120</drugbank-id>
      <name>Phenylalanine</name>
      <description>The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The risk or severity of adverse effects can be increased when Flunisolide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The risk or severity of adverse effects can be increased when Bortezomib is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>The risk or severity of adverse effects can be increased when Cladribine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The risk or severity of adverse effects can be increased when Carmustine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The risk or severity of adverse effects can be increased when Amsacrine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The risk or severity of adverse effects can be increased when Chlorambucil is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00293</drugbank-id>
      <name>Raltitrexed</name>
      <description>The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00309</drugbank-id>
      <name>Vindesine</name>
      <description>The risk or severity of adverse effects can be increased when Vindesine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>The risk or severity of adverse effects can be increased when Floxuridine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00352</drugbank-id>
      <name>Tioguanine</name>
      <description>The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The risk or severity of adverse effects can be increased when Vinorelbine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00380</drugbank-id>
      <name>Dexrazoxane</name>
      <description>The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The risk or severity of adverse effects can be increased when Betamethasone is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The risk or severity of adverse effects can be increased when Teniposide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00446</drugbank-id>
      <name>Chloramphenicol</name>
      <description>The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Lenalidomide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00488</drugbank-id>
      <name>Altretamine</name>
      <description>The risk or severity of adverse effects can be increased when Altretamine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of adverse effects can be increased when Zidovudine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The risk or severity of adverse effects can be increased when Cisplatin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The risk or severity of adverse effects can be increased when Vincristine is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Propylthiouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pentostatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluocinolone acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Linezolid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Clofarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pemetrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mycophenolate mofetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Daunorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Tretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Etoposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dacarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Temozolomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Penicillamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Sirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00888</drugbank-id>
      <name>Mechlorethamine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mechlorethamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Azacitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Carboplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dactinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cytarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Azathioprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Doxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Hydroxyurea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01008</drugbank-id>
      <name>Busulfan</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Busulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mycophenolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Topotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mercaptopurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Melphalan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01073</drugbank-id>
      <name>Fludarabine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fludarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Flucytosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Capecitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Procarbazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Idarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ifosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Estramustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mitoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Lomustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dasatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01257</drugbank-id>
      <name>Eculizumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Eculizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01262</drugbank-id>
      <name>Decitabine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Decitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01280</drugbank-id>
      <name>Nelarabine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Nelarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Colchicine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01423</drugbank-id>
      <name>Stepronin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Stepronin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Hydroxychloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Castanospermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02806</drugbank-id>
      <name>2-Methoxyethanol</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with 2-Methoxyethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03523</drugbank-id>
      <name>Brequinar</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Brequinar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04572</drugbank-id>
      <name>Thiotepa</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Thiotepa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04845</drugbank-id>
      <name>Ixabepilone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ixabepilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pirfenidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Belinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05258</drugbank-id>
      <name>Interferon alfa</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Interferon alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05259</drugbank-id>
      <name>Glatiramer</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Glatiramer.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05260</drugbank-id>
      <name>Gallium nitrate</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Gallium nitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05459</drugbank-id>
      <name>Briakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Briakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05472</drugbank-id>
      <name>omega interferon</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with omega interferon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06612</drugbank-id>
      <name>Mepolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mepolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06662</drugbank-id>
      <name>Abetimus</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Abetimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06681</drugbank-id>
      <name>Belatacept</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Belatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Bendamustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cabazitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pralatrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08059</drugbank-id>
      <name>Wortmannin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Wortmannin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Brentuximab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Eribulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ruxolitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Carfilzomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08908</drugbank-id>
      <name>Dimethyl fumarate</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dimethyl fumarate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pomalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09033</drugbank-id>
      <name>Vedolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Vedolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Tedizolid phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Blinatumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ibrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Palbociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Olaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Vilanterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Peginterferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09312</drugbank-id>
      <name>Antilymphocyte immunoglobulin (horse)</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Antilymphocyte immunoglobulin (horse).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11569</drugbank-id>
      <name>Ixekizumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ixekizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11580</drugbank-id>
      <name>Ravulizumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ravulizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11616</drugbank-id>
      <name>Pirarubicin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pirarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11693</drugbank-id>
      <name>Voclosporin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Voclosporin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11708</drugbank-id>
      <name>Peficitinib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Peficitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11767</drugbank-id>
      <name>Sarilumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Sarilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11776</drugbank-id>
      <name>Brodalumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Brodalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11803</drugbank-id>
      <name>Sirukumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Sirukumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Baricitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11834</drugbank-id>
      <name>Guselkumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Guselkumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12025</drugbank-id>
      <name>Triptolide</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Triptolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12612</drugbank-id>
      <name>Ozanimod</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ozanimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mizoribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12692</drugbank-id>
      <name>Gusperimus</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Gusperimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cepeginterferon alfa-2B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12902</drugbank-id>
      <name>Trofosfamide</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Trofosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12947</drugbank-id>
      <name>Doxifluridine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Doxifluridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12991</drugbank-id>
      <name>Deoxyspergualin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Deoxyspergualin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12996</drugbank-id>
      <name>Acteoside</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Acteoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13014</drugbank-id>
      <name>Hypericin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Hypericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13068</drugbank-id>
      <name>9-(N-methyl-L-isoleucine)-cyclosporin A</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluocortin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13241</drugbank-id>
      <name>Begelomab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Begelomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluperolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Formocortal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluclorolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14219</drugbank-id>
      <name>Monomethyl fumarate</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Monomethyl fumarate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14762</drugbank-id>
      <name>Risankizumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Risankizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14919</drugbank-id>
      <name>Rozanolixizumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Rozanolixizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15253</drugbank-id>
      <name>Bleselumab</name>
      <description>The risk or severity of adverse effects can be increased when Fluorouracil is combined with Bleselumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>The risk or severity of adverse effects can be increased when Epirubicin is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09185</drugbank-id>
      <name>Viloxazine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Viloxazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Pentobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Tranylcypromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01006</drugbank-id>
      <name>Letrozole</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Letrozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01085</drugbank-id>
      <name>Pilocarpine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Pilocarpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01110</drugbank-id>
      <name>Miconazole</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Miconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04540</drugbank-id>
      <name>Cholesterol</name>
      <description>Cholesterol may increase the excretion rate of Fluorouracil which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09046</drugbank-id>
      <name>Metreleptin</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Metreleptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00205</drugbank-id>
      <name>Pyrimethamine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Pyrimethamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The metabolism of Ketoprofen can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin human</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin lispro</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Insulin lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin glargine</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Insulin glargine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin pork</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00170</drugbank-id>
      <name>Menadione</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Menadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00388</drugbank-id>
      <name>Phenylephrine</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Phenylephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Meperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00607</drugbank-id>
      <name>Nafcillin</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Nafcillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00745</drugbank-id>
      <name>Modafinil</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Modafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin aspart</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Insulin aspart.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin detemir</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Insulin detemir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin glulisine</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Insulin glulisine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05115</drugbank-id>
      <name>NN344</name>
      <description>The metabolism of Fluorouracil can be increased when combined with NN344.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06413</drugbank-id>
      <name>Armodafinil</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Armodafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06732</drugbank-id>
      <name>beta-Naphthoflavone</name>
      <description>The metabolism of Fluorouracil can be increased when combined with beta-Naphthoflavone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09564</drugbank-id>
      <name>Insulin degludec</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Insulin degludec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Insulin peglispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11568</drugbank-id>
      <name>Insulin tregopil</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Insulin tregopil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09456</drugbank-id>
      <name>Insulin beef</name>
      <description>The metabolism of Insulin beef can be increased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Amphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Memantine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00636</drugbank-id>
      <name>Clofibrate</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Clofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01011</drugbank-id>
      <name>Metyrapone</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Metyrapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01213</drugbank-id>
      <name>Fomepizole</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Fomepizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Eletriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00238</drugbank-id>
      <name>Nevirapine</name>
      <description>The metabolism of Fluorouracil can be decreased when combined with Nevirapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>The metabolism of Flurazepam can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The metabolism of Methoxyflurane can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The metabolism of Halothane can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The metabolism of Flunitrazepam can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>The metabolism of Clomethiazole can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09274</drugbank-id>
      <name>Artesunate</name>
      <description>The metabolism of Artesunate can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09327</drugbank-id>
      <name>Tegafur-uracil</name>
      <description>The metabolism of Tegafur-uracil can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11586</drugbank-id>
      <name>Asunaprevir</name>
      <description>The metabolism of Asunaprevir can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04977</drugbank-id>
      <name>Plitidepsin</name>
      <description>The metabolism of Plitidepsin can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The metabolism of Cenobamate can be decreased when combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>The serum concentration of Fluorouracil can be increased when it is combined with Lasmiditan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09103</drugbank-id>
      <name>Ancestim</name>
      <description>The risk or severity of cytotoxicity can be increased when Ancestim is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>Pravastatin may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>Pantoprazole may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>Nelfinavir may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>Diethylstilbestrol may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>Gefitinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>Omeprazole may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>Progesterone may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>Lansoprazole may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00470</drugbank-id>
      <name>Dronabinol</name>
      <description>Dronabinol may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>Estradiol may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>Buprenorphine may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>Telmisartan may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>Ezetimibe may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01051</drugbank-id>
      <name>Novobiocin</name>
      <description>Novobiocin may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01094</drugbank-id>
      <name>Hesperetin</name>
      <description>Hesperetin may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>Rabeprazole may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>Genistein may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>Topiroxostat may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02115</drugbank-id>
      <name>Daidzin</name>
      <description>Daidzin may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>Fusidic acid may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03467</drugbank-id>
      <name>Naringenin</name>
      <description>Naringenin may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04216</drugbank-id>
      <name>Quercetin</name>
      <description>Quercetin may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>Taurocholic acid may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04881</drugbank-id>
      <name>Elacridar</name>
      <description>Elacridar may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>Dovitinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>Eltrombopag may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>Simeprevir may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>Safinamide may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08828</drugbank-id>
      <name>Vismodegib</name>
      <description>Vismodegib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>Rilpivirine may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>Regorafenib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>Afatinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>Cannabidiol may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09065</drugbank-id>
      <name>Cobicistat</name>
      <description>Cobicistat may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09102</drugbank-id>
      <name>Daclatasvir</name>
      <description>Daclatasvir may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>Dasabuvir may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09291</drugbank-id>
      <name>Rolapitant</name>
      <description>Rolapitant may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09297</drugbank-id>
      <name>Paritaprevir</name>
      <description>Paritaprevir may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11363</drugbank-id>
      <name>Alectinib</name>
      <description>Alectinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>Venetoclax may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11613</drugbank-id>
      <name>Velpatasvir</name>
      <description>Velpatasvir may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>Isavuconazole may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>Dacomitinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11995</drugbank-id>
      <name>Avatrombopag</name>
      <description>Avatrombopag may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>Abemaciclib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12010</drugbank-id>
      <name>Fostamatinib</name>
      <description>Fostamatinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>Voxilaprevir may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>Letermovir may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>Gilteritinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>Brigatinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>Rucaparib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>Enasidenib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13878</drugbank-id>
      <name>Pibrentasvir</name>
      <description>Pibrentasvir may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13879</drugbank-id>
      <name>Glecaprevir</name>
      <description>Glecaprevir may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>Estradiol acetate may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>Estradiol benzoate may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>Estradiol cypionate may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>Estradiol dienanthate may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>Estradiol valerate may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14009</drugbank-id>
      <name>Medical Cannabis</name>
      <description>Medical Cannabis may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14011</drugbank-id>
      <name>Nabiximols</name>
      <description>Nabiximols may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>Fedratinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12941</drugbank-id>
      <name>Darolutamide</name>
      <description>Darolutamide may decrease the excretion rate of Fluorouracil which could result in a higher serum level.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.58</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.86e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.66</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>fluorouracil</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>130.0772</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>130.017855555</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>FC1=CNC(=O)NC1=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C4H3FN2O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>GHASVSINZRGABV-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>58.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>26.17</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>9.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>7.76</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>1.11E+004 mg/L (at 22 °C)</value>
      <source>BURR,A &amp; BUNDGAARD,H (1985)</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>282-283</value>
      <source>Heidelberger, C. and Duschinsky, R.; US. Patent 2,802,005; August 6, 1957. Heidelberger, C. and Duschinsky, R.; U.S.Patent 2,885,396; May 5, 1959.</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.89</value>
      <source>HANSCH,C ET AL. (1995)</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.07</value>
      <source>ADME Research, USCD</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>8.02</value>
      <source>SANGSTER (1994)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>6311</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>46345</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>3385</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508557</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07649</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00584</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>3268</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50340677</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA128406956</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>URF</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000829</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Fluorouracil</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL185</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/carac.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/fluorouracil.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000469</smpdb-id>
      <name>Capecitabine Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00371</drugbank-id>
          <name>Meprobamate</name>
        </drug>
        <drug>
          <drugbank-id>DB00544</drugbank-id>
          <name>Fluorouracil</name>
        </drug>
        <drug>
          <drugbank-id>DB01101</drugbank-id>
          <name>Capecitabine</name>
        </drug>
        <drug>
          <drugbank-id>DB03147</drugbank-id>
          <name>Flavin adenine dinucleotide</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P04818</uniprot-id>
        <uniprot-id>P19971</uniprot-id>
        <uniprot-id>P23141</uniprot-id>
        <uniprot-id>P32320</uniprot-id>
        <uniprot-id>O00337</uniprot-id>
      </enzymes>
    </pathway>
    <pathway>
      <smpdb-id>SMP0000470</smpdb-id>
      <name>Fluorouracil Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00544</drugbank-id>
          <name>Fluorouracil</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P04818</uniprot-id>
      </enzymes>
    </pathway>
    <pathway>
      <smpdb-id>SMP0000607</smpdb-id>
      <name>Capecitabine Metabolism Pathway</name>
      <category>drug_metabolism</category>
      <drugs>
        <drug>
          <drugbank-id>DB00371</drugbank-id>
          <name>Meprobamate</name>
        </drug>
        <drug>
          <drugbank-id>DB00544</drugbank-id>
          <name>Fluorouracil</name>
        </drug>
        <drug>
          <drugbank-id>DB01101</drugbank-id>
          <name>Capecitabine</name>
        </drug>
        <drug>
          <drugbank-id>DB03147</drugbank-id>
          <name>Flavin adenine dinucleotide</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P04818</uniprot-id>
        <uniprot-id>P19971</uniprot-id>
        <uniprot-id>P23141</uniprot-id>
        <uniprot-id>P32320</uniprot-id>
        <uniprot-id>O00337</uniprot-id>
      </enzymes>
    </pathway>
    <pathway>
      <smpdb-id>SMP0000608</smpdb-id>
      <name>Fluorouracil Metabolism Pathway</name>
      <category>drug_metabolism</category>
      <drugs>
        <drug>
          <drugbank-id>DB00544</drugbank-id>
          <name>Fluorouracil</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P04818</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions>
    <reaction>
      <protein-name>Thymidylate synthase</protein-name>
      <gene-symbol>TYMS</gene-symbol>
      <uniprot-id>P04818</uniprot-id>
      <rs-id>rs34743033</rs-id>
      <allele>TSER*2</allele>
      <adverse-reaction>(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3/4</adverse-reaction>
      <description>Patients with this genotype have increased risk of severe neutropenia or severe diarrhea with [drug; fluorouracil].</description>
      <pubmed-id>16818689</pubmed-id>
    </reaction>
    <reaction>
      <protein-name>Dihydropyrimidine dehydrogenase [NADP(+)]</protein-name>
      <gene-symbol>DPYD</gene-symbol>
      <uniprot-id>Q12882</uniprot-id>
      <rs-id>rs1801265</rs-id>
      <allele/>
      <adverse-reaction>C allele</adverse-reaction>
      <description>Patients with this genotype have reduced metabolism of fluorouracil and increased risk of toxicity.</description>
      <pubmed-id>17848752</pubmed-id>
    </reaction>
    <reaction>
      <protein-name>Glutathione S-transferase P</protein-name>
      <gene-symbol>GSTP1</gene-symbol>
      <uniprot-id>P09211</uniprot-id>
      <rs-id>rs1695</rs-id>
      <allele/>
      <adverse-reaction>A allele</adverse-reaction>
      <description>Patients with this genotype have increased risk of toxicity with fluorouracil</description>
      <pubmed-id>18540691</pubmed-id>
    </reaction>
    <reaction>
      <protein-name>Dihydropyrimidine dehydrogenase [NADP(+)]</protein-name>
      <gene-symbol>DPYD</gene-symbol>
      <uniprot-id>Q12882</uniprot-id>
      <rs-id>rs3918290</rs-id>
      <allele/>
      <adverse-reaction>A allele</adverse-reaction>
      <description>Patients with this genotype have reduced metabolism of fluorouracil and increased risk of toxicity.</description>
      <pubmed-id>18299612</pubmed-id>
    </reaction>
    <reaction>
      <protein-name>Dihydropyrimidine dehydrogenase [NADP(+)]</protein-name>
      <gene-symbol>DPYD</gene-symbol>
      <uniprot-id>Q12882</uniprot-id>
      <rs-id>rs67376798</rs-id>
      <allele/>
      <adverse-reaction>T &gt; A</adverse-reaction>
      <description>Patients with this genotype have reduced metabolism of fluorouracil and increased risk of toxicity.</description>
      <pubmed-id>23603345</pubmed-id>
    </reaction>
    <reaction>
      <protein-name>Dihydropyrimidine dehydrogenase [NADP(+)]</protein-name>
      <gene-symbol>DPYD</gene-symbol>
      <uniprot-id>Q12882</uniprot-id>
      <rs-id>rs3918290</rs-id>
      <allele>DPYD*2A</allele>
      <adverse-reaction>G &gt; A</adverse-reaction>
      <description>The presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from fluorouracil therapy.</description>
      <pubmed-id>23988873</pubmed-id>
    </reaction>
    <reaction>
      <protein-name>Dihydropyrimidine dehydrogenase [NADP(+)]</protein-name>
      <gene-symbol>DPYD</gene-symbol>
      <uniprot-id>Q12882</uniprot-id>
      <rs-id>rs55886062</rs-id>
      <allele>DPYD*13</allele>
      <adverse-reaction>A &gt; C</adverse-reaction>
      <description>The presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from fluorouracil therapy.</description>
      <pubmed-id>23988873</pubmed-id>
    </reaction>
    <reaction>
      <protein-name>Dihydropyrimidine dehydrogenase [NADP(+)]</protein-name>
      <gene-symbol>DPYD</gene-symbol>
      <uniprot-id>Q12882</uniprot-id>
      <rs-id>rs67376798</rs-id>
      <allele/>
      <adverse-reaction>T &gt; A</adverse-reaction>
      <description>The presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from fluorouracil therapy.</description>
      <pubmed-id>23988873</pubmed-id>
    </reaction>
    <reaction>
      <protein-name>Dihydropyrimidine dehydrogenase [NADP(+)]</protein-name>
      <gene-symbol>DPYD</gene-symbol>
      <uniprot-id>Q12882</uniprot-id>
      <rs-id>rs1801158</rs-id>
      <allele>DPYD*4</allele>
      <adverse-reaction>G &gt; A</adverse-reaction>
      <description>The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from fluorouracil therapy.</description>
      <pubmed-id>23988873</pubmed-id>
    </reaction>
    <reaction>
      <protein-name>Dihydropyrimidine dehydrogenase [NADP(+)]</protein-name>
      <gene-symbol>DPYD</gene-symbol>
      <uniprot-id>Q12882</uniprot-id>
      <rs-id>rs1801159</rs-id>
      <allele>DPYD*5</allele>
      <adverse-reaction>A &gt; G</adverse-reaction>
      <description>The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from fluorouracil therapy.</description>
      <pubmed-id>23988873</pubmed-id>
    </reaction>
    <reaction>
      <protein-name>Dihydropyrimidine dehydrogenase [NADP(+)]</protein-name>
      <gene-symbol>DPYD</gene-symbol>
      <uniprot-id>Q12882</uniprot-id>
      <rs-id>rs1801160</rs-id>
      <allele>DPYD*6</allele>
      <adverse-reaction>G &gt; A</adverse-reaction>
      <description>The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from fluorouracil therapy.</description>
      <pubmed-id>23988873</pubmed-id>
    </reaction>
    <reaction>
      <protein-name>Dihydropyrimidine dehydrogenase [NADP(+)]</protein-name>
      <gene-symbol>DPYD</gene-symbol>
      <uniprot-id>Q12882</uniprot-id>
      <rs-id>rs1801265</rs-id>
      <allele>DPYD*9A</allele>
      <adverse-reaction>T &gt; C</adverse-reaction>
      <description>The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from fluorouracil therapy.</description>
      <pubmed-id>23988873</pubmed-id>
    </reaction>
  </snp-adverse-drug-reactions>
  <targets>
    <target>
      <id>BE0000324</id>
      <name>Thymidylate synthase</name>
      <organism>Humans</organism>
      <actions>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5097</ref-id>
            <pubmed-id>16538493</pubmed-id>
            <citation>Formentini A, Sander S, Denzer S, Straeter J, Henne-Bruns D, Kornmann M: Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker? Int J Colorectal Dis. 2007 Jan;22(1):49-55. Epub 2006 Mar 15.</citation>
          </article>
          <article>
            <ref-id>A5098</ref-id>
            <pubmed-id>16563096</pubmed-id>
            <citation>Huang CL, Yokomise H, Fukushima M, Kinoshita M: Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncol. 2006 Apr;2(2):289-99.</citation>
          </article>
          <article>
            <ref-id>A5099</ref-id>
            <pubmed-id>16596248</pubmed-id>
            <citation>Fernandez-Contreras ME, Sanchez-Prudencio S, Sanchez-Hernandez JJ, Garcia de Paredes ML, Gisbert JP, Roda-Navarro P, Gamallo C: Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. Int J Oncol. 2006 May;28(5):1303-10.</citation>
          </article>
          <article>
            <ref-id>A5100</ref-id>
            <pubmed-id>16609021</pubmed-id>
            <citation>Garcia V, Garcia JM, Pena C, Silva J, Dominguez G, Hurtado A, Alonso I, Rodriguez R, Provencio M, Bonilla F: Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2095-100.</citation>
          </article>
          <article>
            <ref-id>A5101</ref-id>
            <pubmed-id>16719540</pubmed-id>
            <citation>Ploylearmsaeng SA, Fuhr U, Jetter A: How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet. 2006;45(6):567-92.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A5102</ref-id>
            <pubmed-id>15353299</pubmed-id>
            <citation>Rustum YM: Thymidylate synthase: a critical target in cancer therapy? Front Biosci. 2004 Sep 1;9:2467-73.</citation>
          </article>
          <article>
            <ref-id>A33220</ref-id>
            <pubmed-id>25544046</pubmed-id>
            <citation>Singh V, Brecik M, Mukherjee R, Evans JC, Svetlikova Z, Blasko J, Surade S, Blackburn J, Warner DF, Mikusova K, Mizrahi V: The complex mechanism of antimycobacterial action of 5-fluorouracil. Chem Biol. 2015 Jan 22;22(1):63-75. doi: 10.1016/j.chembiol.2014.11.006. Epub 2014 Dec 24.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P04818" source="Swiss-Prot">
        <name>Thymidylate synthase</name>
        <general-function>Thymidylate synthase activity</general-function>
        <specific-function>Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.</specific-function>
        <gene-name>TYMS</gene-name>
        <locus>18p11.32</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.0</theoretical-pi>
        <molecular-weight>35715.65</molecular-weight>
        <chromosome-location>18</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12441</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>TYMS</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X02308</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>37479</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2642</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04818</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TYSY_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.1.1.45</synonym>
          <synonym>TS</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036991|Thymidylate synthase
MPVAGSELPRRPLPPAAQERDAEPRPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFG
MQARYSLRDEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDS
LGFSTREEGDLGPVYGFQWRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMC
AWNPRDLPLMALPPCHALCQFYVVNSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHI
TGLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRPFPKLRILRKVEKIDDFKAEDFQIEG
YNPHPTIKMEMAV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010247|Thymidylate synthase (TYMS)
ATGCCTGTGGCCGGCTCGGAGCTGCCGCGCCGGCCCTTGCCCCCCGCCGCACAGGAGCGG
GACGCCGAGCCGCGTCCGCCGCACGGGGAGCTGCAGTACCTGGGGCAGATCCAACACATC
CTCCGCTGCGGCGTCAGGAAGGACGACCGCACGGGCACCGGCACCCTGTCGGTATTCGGC
ATGCAGGCGCGCTACAGCCTGAGAGATGAATTCCCTCTGCTGACAACCAAACGTGTGTTC
TGGAAGGGTGTTTTGGAGGAGTTGCTGTGGTTTATCAAGGGATCCACAAATGCTAAAGAG
CTGTCTTCCAAGGGAGTGAAAATCTGGGATGCCAATGGATCCCGAGACTTTTTGGACAGC
CTGGGATTCTCCACCAGAGAAGAAGGGGACTTGGGCCCAGTTTATGGCTTCCAGTGGAGG
CATTTTGGGGCAGAATACAGAGATATGGAATCAGATTATTCAGGACAGGGAGTTGACCAA
CTGCAAAGAGTGATTGACACCATCAAAACCAACCCTGACGACAGAAGAATCATCATGTGC
GCTTGGAATCCAAGAGATCTTCCTCTGATGGCGCTGCCTCCATGCCATGCCCTCTGCCAG
TTCTATGTGGTGAACAGTGAGCTGTCCTGCCAGCTGTACCAGAGATCGGGAGACATGGGC
CTCGGTGTGCCTTTCAACATCGCCAGCTACGCCCTGCTCACGTACATGATTGCGCACATC
ACGGGCCTGAAGCCAGGTGACTTTATACACACTTTGGGAGATGCACATATTTACCTGAAT
CACATCGAGCCACTGAAAATTCAGCTTCAGCGAGAACCCAGACCTTTCCCAAAGCTCAGG
ATTCTTCGAAAAGTTGAGAAAATTGATGACTTCAAAGCTGAAGACTTTCAGATTGAAGGG
TACAATCCGCATCCAACTATTAAAATGGAAATGGCTGTTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00303</identifier>
            <name>Thymidylat_synt</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial inner membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleolus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cofactor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>folic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>mRNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nucleotide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thymidylate synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cartilage development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>deoxyribonucleoside monophosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>developmental growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dTMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dTTP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dUMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immortalization of host cell by virus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intestinal epithelial cell maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organ regeneration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleoside biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription involved in G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cytokine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to folic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucocorticoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to organophosphorus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to progesterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin A</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tetrahydrofolate interconversion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>uracil metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0004796</id>
      <name>DNA</name>
      <organism>Humans</organism>
      <actions>
        <action>incorporation into and destabilization</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16762</ref-id>
            <pubmed-id>18979208</pubmed-id>
            <citation>Wyatt MD, Wilson DM 3rd: Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci. 2009 Mar;66(5):788-99. doi: 10.1007/s00018-008-8557-5.</citation>
          </article>
          <article>
            <ref-id>A16763</ref-id>
            <pubmed-id>9264308</pubmed-id>
            <citation>Ghoshal K, Jacob ST: An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol. 1997 Jun 1;53(11):1569-75.</citation>
          </article>
          <article>
            <ref-id>A841</ref-id>
            <pubmed-id>12724731</pubmed-id>
            <citation>Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8.</citation>
          </article>
          <article>
            <ref-id>A842</ref-id>
            <pubmed-id>15032669</pubmed-id>
            <citation>Petty RD, Cassidy J: Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets. 2004 Mar;4(2):191-204.</citation>
          </article>
          <article>
            <ref-id>A33220</ref-id>
            <pubmed-id>25544046</pubmed-id>
            <citation>Singh V, Brecik M, Mukherjee R, Evans JC, Svetlikova Z, Blasko J, Surade S, Blackburn J, Warner DF, Mikusova K, Mizrahi V: The complex mechanism of antimycobacterial action of 5-fluorouracil. Chem Biol. 2015 Jan 22;22(1):63-75. doi: 10.1016/j.chembiol.2014.11.006. Epub 2014 Dec 24.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
    <target position="6">
      <id>BE0004810</id>
      <name>RNA</name>
      <organism>Humans</organism>
      <actions>
        <action>incorporation into and destabilization</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16762</ref-id>
            <pubmed-id>18979208</pubmed-id>
            <citation>Wyatt MD, Wilson DM 3rd: Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci. 2009 Mar;66(5):788-99. doi: 10.1007/s00018-008-8557-5.</citation>
          </article>
          <article>
            <ref-id>A16763</ref-id>
            <pubmed-id>9264308</pubmed-id>
            <citation>Ghoshal K, Jacob ST: An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol. 1997 Jun 1;53(11):1569-75.</citation>
          </article>
          <article>
            <ref-id>A841</ref-id>
            <pubmed-id>12724731</pubmed-id>
            <citation>Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330-8.</citation>
          </article>
          <article>
            <ref-id>A842</ref-id>
            <pubmed-id>15032669</pubmed-id>
            <citation>Petty RD, Cassidy J: Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Curr Cancer Drug Targets. 2004 Mar;4(2):191-204.</citation>
          </article>
          <article>
            <ref-id>A33220</ref-id>
            <pubmed-id>25544046</pubmed-id>
            <citation>Singh V, Brecik M, Mukherjee R, Evans JC, Svetlikova Z, Blasko J, Surade S, Blackburn J, Warner DF, Mikusova K, Mizrahi V: The complex mechanism of antimycobacterial action of 5-fluorouracil. Chem Biol. 2015 Jan 22;22(1):63-75. doi: 10.1016/j.chembiol.2014.11.006. Epub 2014 Dec 24.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes>
    <enzyme>
      <id>BE0002793</id>
      <name>Cytochrome P450 2C9</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A33219</ref-id>
            <pubmed-id>16445595</pubmed-id>
            <citation>Gunes A, Coskun U, Boruban C, Gunel N, Babaoglu MO, Sencan O, Bozkurt A, Rane A, Hassan M, Zengil H, Yasar U: Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. Basic Clin Pharmacol Toxicol. 2006 Feb;98(2):197-200. doi: 10.1111/j.1742-7843.2006.pto_304.x.</citation>
          </article>
          <article>
            <ref-id>A33222</ref-id>
            <pubmed-id>10473927</pubmed-id>
            <citation>Brown MC: An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature. Chemotherapy. 1999 Sep-Oct;45(5):392-5. doi: 10.1159/000007230.</citation>
          </article>
          <article>
            <ref-id>A33223</ref-id>
            <pubmed-id>11724084</pubmed-id>
            <citation>Gilbar PJ, Brodribb TR: Phenytoin and fluorouracil interaction. Ann Pharmacother. 2001 Nov;35(11):1367-70. doi: 10.1345/aph.1A051.</citation>
          </article>
          <article>
            <ref-id>A33224</ref-id>
            <pubmed-id>15452381</pubmed-id>
            <citation>Karadag O, Babaoglu MO, Altundag K, Elkiran T, Yasar U, Bozkurt A: 5-Fluorouracil-induced coronary spasm: may inhibition of hyperpolarization factors produced by CYP2C enzymes be the cause? Oncology. 2004;66(6):510-1. doi: 10.1159/000079506.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P11712" source="Swiss-Prot">
        <name>Cytochrome P450 2C9</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.</specific-function>
        <gene-name>CYP2C9</gene-name>
        <locus>10q24</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.99</theoretical-pi>
        <molecular-weight>55627.365</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2623</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2C9</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AY341248</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1326</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11712</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2C9_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>(R)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 6-monooxygenase</synonym>
          <synonym>(S)-limonene 7-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP2C10</synonym>
          <synonym>CYPIIC9</synonym>
          <synonym>Cytochrome P-450MP</synonym>
          <synonym>Cytochrome P450 MP-4</synonym>
          <synonym>Cytochrome P450 MP-8</synonym>
          <synonym>Cytochrome P450 PB-1</synonym>
          <synonym>S-mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005471|Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016893|Cytochrome P450 2C9 (CYP2C9)
ATGGATTCTCTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCACTCTGG
AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA
AATATCCTACAGATAGGTATTAAGGACATCAGCAAATCCTTAACCAATCTCTCAAAGGTC
TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGAAACCCATAGTGGTGCTGCATGGATAT
GAAGCAGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCATTTTC
CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATTGTTTTCAGCAATGGAAAGAAATGG
AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
ATTATTTTCCATAAACGTTTTGATTATAAAGATCAGCAATTTCTTAACTTAATGGAAAAG
TTGAATGAAAACATCAAGATTTTGAGCAGCCCCTGGATCCAGATCTGCAATAATTTTTCT
CCTATCATTGATTACTTCCCGGGAACTCACAACAAATTACTTAAAAACGTTGCTTTTATG
AAAAGTTATATTTTGGAAAAAGTAAAAGAACACCAAGAATCAATGGACATGAACAACCCT
CAGGACTTTATTGATTGCTTCCTGATGAAAATGGAGAAGGAAAAGCACAACCAACCATCT
GAATTTACTATTGAAAGCTTGGAAAACACTGCAGTTGACTTGTTTGGAGCTGGGACAGAG
ACGACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCCTGCATGCAA
GACAGGAGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATTGAC
CTTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACATTAAATTCAGAAACTATCTC
ATTCCCAAGGGCACAACCATATTAATTTCCCTGACTTCTGTGCTACATGACAACAAAGAA
TTTCCCAACCCAGAGATGTTTGACCCTCATCACTTTCTGGATGAAGGTGGCAATTTTAAG
AAAAGTAAATACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAAGCCCTG
GCCGGCATGGAGCTGTTTTTATTCCTGACCTCCATTTTACAGAACTTTAACCTGAAATCT
CTGGTTGACCCAAAGAACCTTGACACCACTCCAGTTGTCAATGGATTTGCCTCTGTGCCG
CCCTTCTACCAGCTGTGCTTCATTCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(R)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 6-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>(S)-limonene 7-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular amide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocarboxylic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urea metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme>
      <id>BE0002433</id>
      <name>Cytochrome P450 1A2</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A37953</ref-id>
            <pubmed-id>11095583</pubmed-id>
            <citation>Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T: Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.</citation>
          </article>
          <article>
            <ref-id>A39050</ref-id>
            <pubmed-id>11353746</pubmed-id>
            <citation>Yamazaki H, Komatsu T, Takemoto K, Shimada N, Nakajima M, Yokoi T: Rat cytochrome p450 1A and 3A enzymes involved in bioactivation of tegafur to 5-fluorouracil and autoinduced by tegafur in liver microsomes. Drug Metab Dispos. 2001 Jun;29(6):794-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05177" source="Swiss-Prot">
        <name>Cytochrome P450 1A2</name>
        <general-function>Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.</specific-function>
        <gene-name>CYP1A2</gene-name>
        <locus>15q24</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.43</theoretical-pi>
        <molecular-weight>58293.76</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2596</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP1A2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Z00036</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1319</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05177</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP1A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYPIA2</synonym>
          <synonym>Cytochrome P(3)450</synonym>
          <synonym>Cytochrome P450 4</synonym>
          <synonym>Cytochrome P450-P3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004778|Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2)
ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>demethylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron carrier activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular respiration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cadmium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dibenzo-p-dioxin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>methylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocarboxylic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative deethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>porphyrin-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to immobilization stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toxin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme>
      <id>BE0002193</id>
      <name>Thymidine phosphorylase</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15123</ref-id>
            <pubmed-id>21332317</pubmed-id>
            <citation>Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S: 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65. doi: 10.2217/pgs.10.167.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P19971" source="Swiss-Prot">
        <name>Thymidine phosphorylase</name>
        <general-function>Transferase activity, transferring pentosyl groups</general-function>
        <specific-function>May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro.Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis.</specific-function>
        <gene-name>TYMP</gene-name>
        <locus>22q13|22q13.33</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.19</theoretical-pi>
        <molecular-weight>49954.965</molecular-weight>
        <chromosome-location>22</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3148</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ECGF1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M63193</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>189701</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P19971</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TYPH_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.2.4</synonym>
          <synonym>ECGF1</synonym>
          <synonym>Gliostatin</synonym>
          <synonym>PD-ECGF</synonym>
          <synonym>Platelet-derived endothelial cell growth factor</synonym>
          <synonym>TdRPase</synonym>
          <synonym>TP</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004303|Thymidine phosphorylase
MAALMTPGTGAPPAPGDFSGEGSQGLPDPSPEPKQLPELIRMKRDGGRLSEADIRGFVAA
VVNGSAQGAQIGAMLMAIRLRGMDLEETSVLTQALAQSGQQLEWPEAWRQQLVDKHSTGG
VGDKVSLVLAPALAACGCKVPMISGRGLGHTGGTLDKLESIPGFNVIQSPEQMQVLLDQA
GCCIVGQSEQLVPADGILYAARDVTATVDSLPLITASILSKKLVEGLSALVVDVKFGGAA
VFPNQEQARELAKTLVGVGASLGLRVAAALTAMDKPLGRCVGHALEVEEALLCMDGAGPP
DLRDLVTTLGGALLWLSGHAGTQAQGAARVAAALDDGSALGRFERMLAAQGVDPGLARAL
CSGSPAERRQLLPRAREQEELLAPADGTVELVRALPLALVLHELGAGRSRAGEPLRLGVG
AELLVDVGQRLRRGTPWLRVHRDGPALSGPQSRALQEALVLSDRAPFAAPSPFAELVLPP
QQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020602|Thymidine phosphorylase (TYMP)
ATGGCAGCCTTGATGACCCCGGGAACCGGGGCCCCACCCGCGCCTGGTGACTTCTCCGGG
GAAGGGAGCCAGGGACTTCCCGACCCTTCGCCAGAGCCCAAGCAGCTCCCGGAGCTGATC
CGCATGAAGCGAGACGGAGGCCGCCTGAGCGAAGCGGACATCAGGGGCTTCGTGGCCGCT
GTGGTGAATGGGAGCGCGCAGGGCGCACAGATCGGGGCCATGCTGATGGCCATCCGACTT
CGGGGCATGGATCTGGAGGAGACCTCGGTGCTGACCCAGGCCCTGGCTCAGTCGGGACAG
CAGCTGGAGTGGCCAGAGGCCTGGCGCCAGCAGCTTGTGGACAAGCATTCCACAGGGGGT
GTGGGTGACAAGGTCAGCCTGGTCCTCGCACCTGCCCTGGCGGCATGTGGCTGCAAGGTG
CCAATGATCAGCGGACGTGGTCTGGGGCACACAGGAGGCACCTTGGATAAGCTGGAGTCT
ATTCCTGGATTCAATGTCATCCAGAGCCCAGAGCAGATGCAAGTGCTGCTGGACCAGGCG
GGCTGCTGTATCGTGGGTCAGAGTGAGCAGCTGGTTCCTGCGGACGGAATCCTATATGCA
GCCAGAGATGTGACAGCCACCGTGGACAGCCTGCCACTCATCACAGCCTCCATTCTCAGT
AAGAAACTCGTGGAGGGGCTGTCCGCTCTGGTGGTGGACGTTAAGTTCGGAGGGGCCGCC
GTCTTCCCCAACCAGGAGCAGGCCCGGGAGCTGGCAAAGACGCTGGTTGGCGTGGGAGCC
AGCCTAGGGCTTCGGGTCGCGGCAGCGCTGACCGCCATGGACAAGCCCCTGGGTCGCTGC
GTGGGCCACGCCCTGGAGGTGGAGGAGGCGCTGCTCTGCATGGACGGCGCAGGCCCGCCA
GACTTAAGGGACCTGGTCACCACGCTCGGGGGCGCCCTGCTCTGGCTCAGCGGACACGCG
GGGACTCAGGCCCAGGGCGCTGCCCGGGTGGCCGCGGCGCTGGACGACGGCTCGGCCCTT
GGCCGCTTCGAGCGGATGCTGGCGGCGCAGGGCGTGGATCCCGGTCTGGCCCGAGCCCTG
TGCTCGGGAAGTCCCGCAGAACGCCGGCAGCTGCTGCCTCGCGCCCGGGAGCAGGAGGAG
CTGCTGGCGCCCGCAGATGGCACCGTGGAGCTGGTCCGGGCGCTGCCGCTGGCGCTGGTG
CTGCACGAGCTCGGGGCCGGGCGCAGCCGCGCTGGGGAGCCGCTCCGCCTGGGGGTGGGC
GCAGAGCTGCTGGTCGACGTGGGTCAGAGGCTGCGCCGTGGGACCCCCTGGCTCCGCGTG
CACCGGGACGGCCCCGCGCTCAGCGGCCCGCAGAGCCGCGCCCTGCAGGAGGCGCTCGTA
CTCTCCGACCGCGCGCCATTCGCCGCCCCCTCGCCCTTCGCAGAGCTCGTTCTGCCGCCG
CAGCAATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02885</identifier>
            <name>Glycos_trans_3N</name>
          </pfam>
          <pfam>
            <identifier>PF00591</identifier>
            <name>Glycos_transf_3</name>
          </pfam>
          <pfam>
            <identifier>PF07831</identifier>
            <name>PYNP_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphorylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>platelet-derived growth factor receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyrimidine-nucleoside phosphorylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thymidine phosphorylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transferase activity, transferring pentosyl groups</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitochondrial genome maintenance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleoside catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleoside salvage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleotide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="2">
      <id>BE0000960</id>
      <name>Dihydropyrimidine dehydrogenase [NADP(+)]</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16611</ref-id>
            <pubmed-id>3752956</pubmed-id>
            <citation>Ho DH, Townsend L, Luna MA, Bodey GP: Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res. 1986 Jul-Aug;6(4):781-4.</citation>
          </article>
          <article>
            <ref-id>A16612</ref-id>
            <pubmed-id>8045919</pubmed-id>
            <citation>Keizer HJ, De Bruijn EA, Tjaden UR, De Clercq E: Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine. J Cancer Res Clin Oncol. 1994;120(9):545-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q12882" source="Swiss-Prot">
        <name>Dihydropyrimidine dehydrogenase [NADP(+)]</name>
        <general-function>Protein homodimerization activity</general-function>
        <specific-function>Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil.</specific-function>
        <gene-name>DPYD</gene-name>
        <locus>1p22</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.05</theoretical-pi>
        <molecular-weight>111400.32</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3012</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>DPYD</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U09178</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>558305</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q12882</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DPYD_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.3.1.2</synonym>
          <synonym>DHPDHase</synonym>
          <synonym>Dihydrothymine dehydrogenase</synonym>
          <synonym>Dihydrouracil dehydrogenase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037106|Dihydropyrimidine dehydrogenase [NADP(+)]
MAPVLSKDSADIESILALNPRTQTHATLCSTSAKKLDKKHWKRNPDKNCFNCEKLENNFD
DIKHTTLGERGALREAMRCLKCADAPCQKSCPTNLDIKSFITSIANKNYYGAAKMIFSDN
PLGLTCGMVCPTSDLCVGGCNLYATEEGPINIGGLQQFATEVFKAMSIPQIRNPSLPPPE
KMSEAYSAKIALFGAGPASISCASFLARLGYSDITIFEKQEYVGGLSTSEIPQFRLPYDV
VNFEIELMKDLGVKIICGKSLSVNEMTLSTLKEKGYKAAFIGIGLPEPNKDAIFQGLTQD
QGFYTSKDFLPLVAKGSKAGMCACHSPLPSIRGVVIVLGAGDTAFDCATSALRCGARRVF
IVFRKGFVNIRAVPEEMELAKEEKCEFLPFLSPRKVIVKGGRIVAMQFVRTEQDETGKWN
EDEDQMVHLKADVVISAFGSVLSDPKVKEALSPIKFNRWGLPEVDPETMQTSEAWVFAGG
DVVGLANTTVESVNDGKQASWYIHKYVQSQYGASVSAKPELPLFYTPIDLVDISVEMAGL
KFINPFGLASATPATSTSMIRRAFEAGWGFALTKTFSLDKDIVTNVSPRIIRGTTSGPMY
GPGQSSFLNIELISEKTAAYWCQSVTELKADFPDNIVIASIMCSYNKNDWTELAKKSEDS
GADALELNLSCPHGMGERGMGLACGQDPELVRNICRWVRQAVQIPFFAKLTPNVTDIVSI
ARAAKEGGANGVTATNTVSGLMGLKSDGTPWPAVGIAKRTTYGGVSGTAIRPIALRAVTS
IARALPGFPILATGGIDSAESGLQFLHSGASVLQVCSAIQNQDFTVIEDYCTGLKALLYL
KSIEELQDWDGQSPATVSHQKGKPVPRIAELMDKKLPSFGPYLEQRKKIIAENKIRLKEQ
NVAFSPLKRNCFIPKRPIPTIKDVIGKALQYLGTFGELSNVEQVVAMIDEEMCINCGKCY
MTCNDSGYQAIQFDPETHLPTITDTCTGCTLCLSVCPIVDCIKMVSRTTPYEPKRGVPLS
VNPVC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010674|Dihydropyrimidine dehydrogenase [NADP(+)] (DPYD)
ATGGCCCCTGTGCTCAGTAAGGACTCGGCGGACATCGAGAGTATCCTGGCTTTAAATCCT
CGAACACAAACTCATGCAACTCTGTGTTCCACTTCGGCCAAGAAATTAGACAAGAAACAT
TGGAAAAGAAATCCTGATAAGAACTGCTTTAATTGTGAGAAGCTGGAGAATAATTTTGAT
GACATCAAGCACACGACTCTTGGTGAGCGAGGAGCTCTCCGAGAAGCAATGAGATGCCTG
AAATGTGCAGATGCCCCGTGTCAGAAGAGCTGTCCAACTAATCTTGATATTAAATCATTC
ATCACAAGTATTGCAAACAAGAACTATTATGGAGCTGCTAAGATGATATTTTCTGACAAC
CCACTTGGTCTGACTTGTGGAATGGTATGTCCAACCTCTGATCTTTGTGTAGGTGGATGC
AATTTATATGCCACTGAAGAGGGACCCATTAATATTGGTGGATTGCAGCAATTTGCTACT
GAGGTATTCAAAGCAATGAGTATCCCACAGATCAGAAATCCTTCGCTGCCTCCCCCAGAA
AAAATGTCTGAAGCCTATTCTGCAAAGATTGCTCTTTTTGGTGCTGGGCCTGCAAGTATA
AGTTGTGCTTCCTTTTTGGCTCGATTGGGGTACTCTGACATCACTATATTTGAAAAACAA
GAATATGTTGGTGGTTTAAGTACTTCTGAAATTCCTCAGTTCCGGCTGCCGTATGATGTA
GTGAATTTTGAGATTGAGCTAATGAAGGACCTTGGTGTAAAGATAATTTGCGGTAAAAGC
CTTTCAGTGAATGAAATGACTCTTAGCACTTTGAAAGAAAAAGGCTACAAAGCTGCTTTC
ATTGGAATAGGTTTGCCAGAACCCAATAAAGATGCCATCTTCCAAGGCCTGACGCAGGAC
CAGGGGTTTTATACATCCAAAGACTTTTTGCCACTTGTAGCCAAAGGCAGTAAAGCAGGA
ATGTGCGCCTGTCACTCTCCATTGCCATCGATACGGGGAGTCGTGATTGTACTTGGAGCT
GGAGACACTGCCTTTGACTGTGCAACATCTGCTCTACGTTGTGGAGCTCGCCGTGTGTTC
ATCGTCTTCAGAAAAGGCTTTGTTAATATAAGAGCTGTCCCTGAGGAGATGGAACTTGCT
AAGGAAGAAAAGTGTGAATTTCTGCCATTCCTGTCCCCACGGAAGGTTATAGTAAAAGGT
GGGAGAATTGTTGCTATGCAGTTTGTTCGGACAGAGCAAGATGAAACTGGAAAATGGAAT
GAAGATGAAGATCAGATGGTCCATCTGAAAGCCGATGTGGTCATCAGTGCCTTTGGTTCA
GTTCTGAGTGATCCTAAAGTAAAAGAAGCCTTGAGCCCTATAAAATTTAACAGATGGGGT
CTCCCAGAAGTAGATCCAGAAACTATGCAAACTAGTGAAGCATGGGTATTTGCAGGTGGT
GATGTCGTTGGTTTGGCTAACACTACAGTGGAATCGGTGAATGATGGAAAGCAAGCTTCT
TGGTACATTCACAAATACGTACAGTCACAATATGGAGCTTCCGTTTCTGCCAAGCCTGAA
CTACCCCTCTTTTACACTCCTATTGATCTGGTGGACATTAGTGTAGAAATGGCCGGATTG
AAGTTTATAAATCCTTTTGGTCTTGCTAGCGCAACTCCAGCCACCAGCACATCAATGATT
CGAAGAGCTTTTGAAGCTGGATGGGGTTTTGCCCTCACCAAAACTTTCTCTCTTGATAAG
GACATTGTGACAAATGTTTCCCCCAGAATCATCCGGGGAACCACCTCTGGCCCCATGTAT
GGCCCTGGACAAAGCTCCTTTCTGAATATTGAGCTCATCAGTGAGAAAACGGCTGCATAT
TGGTGTCAAAGTGTCACTGAACTAAAGGCTGACTTTCCAGACAACATTGTGATTGCTAGC
ATTATGTGCAGTTACAATAAAAATGACTGGACGGAACTTGCCAAGAAGTCTGAGGATTCT
GGAGCAGATGCCCTGGAGTTAAATTTATCATGTCCACATGGCATGGGAGAAAGAGGAATG
GGCCTGGCCTGTGGGCAGGATCCAGAGCTGGTGCGGAACATCTGCCGCTGGGTTAGGCAA
GCTGTTCAGATTCCTTTTTTTGCCAAGCTGACCCCAAATGTCACTGATATTGTGAGCATC
GCAAGAGCTGCAAAGGAAGGTGGTGCCAATGGCGTTACAGCCACCAACACTGTCTCAGGT
CTGATGGGATTAAAATCTGATGGCACACCTTGGCCAGCAGTGGGGATTGCAAAGCGAACT
ACATATGGAGGAGTGTCTGGGACAGCAATCAGACCTATTGCTTTGAGAGCTGTGACCTCC
ATTGCTCGTGCTCTGCCTGGATTTCCCATTTTGGCTACTGGTGGAATTGACTCTGCTGAA
AGTGGTCTTCAGTTTCTCCATAGTGGTGCTTCCGTCCTCCAGGTATGCAGTGCCATTCAG
AATCAGGATTTCACTGTGATCGAAGACTACTGCACTGGCCTCAAAGCCCTGCTTTATCTG
AAAAGCATTGAAGAACTACAAGACTGGGATGGACAGAGTCCAGCTACTGTGAGTCACCAG
AAAGGGAAACCAGTTCCACGTATAGCTGAACTCATGGACAAGAAACTGCCAAGTTTTGGA
CCTTATCTGGAACAGCGCAAGAAAATCATAGCAGAAAACAAGATTAGACTGAAAGAACAA
AATGTAGCTTTTTCACCACTTAAGAGAAACTGTTTTATCCCCAAAAGGCCTATTCCTACC
ATCAAGGATGTAATAGGAAAAGCACTGCAGTACCTTGGAACATTTGGTGAATTGAGCAAC
GTAGAGCAAGTTGTGGCTATGATTGATGAAGAAATGTGTATCAACTGTGGTAAATGCTAC
ATGACCTGTAATGATTCTGGCTACCAGGCTATACAGTTTGATCCAGAAACCCACCTGCCC
ACCATAACCGACACTTGTACAGGCTGTACTCTGTGTCTCAGTGTTTGCCCTATTGTCGAC
TGCATCAAAATGGTTTCCAGGACAACACCTTATGAACCAAAGAGAGGCGTACCCTTATCT
GTGAATCCGGTGTGTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07992</identifier>
            <name>Pyr_redox_2</name>
          </pfam>
          <pfam>
            <identifier>PF01180</identifier>
            <name>DHO_dh</name>
          </pfam>
          <pfam>
            <identifier>PF14691</identifier>
            <name>Fer4_20</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>4 iron, 4 sulfur cluster binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dihydropyrimidine dehydrogenase (NADP+) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>flavin adenine dinucleotide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NADP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>beta-alanine biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine nucleobase catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleobase catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleoside catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thymidine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thymine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>uracil catabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="3">
      <id>BE0002456</id>
      <name>Uridine phosphorylase 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16613</ref-id>
            <pubmed-id>16720348</pubmed-id>
            <citation>Yan R, Wan L, Pizzorno G, Cao D: Uridine phosphorylase in breast cancer: a new prognostic factor? Front Biosci. 2006 Sep 1;11:2759-66.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q16831" source="Swiss-Prot">
        <name>Uridine phosphorylase 1</name>
        <general-function>Uridine phosphorylase activity</general-function>
        <specific-function>Catalyzes the reversible phosphorylytic cleavage of uridine and deoxyuridine to uracil and ribose- or deoxyribose-1-phosphate (PubMed:7488099). The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis.</specific-function>
        <gene-name>UPP1</gene-name>
        <locus>7p12.3</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.95</theoretical-pi>
        <molecular-weight>33934.005</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12576</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>UPP1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X90858</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q16831</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>UPP1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.2.3</synonym>
          <synonym>UP</synonym>
          <synonym>UPase 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004823|Uridine phosphorylase 1
MAATGANAEKAESHNDCPVRLLNPNIAKMKEDILYHFNLTTSRHNFPALFGDVKFVCVGG
SPSRMKAFIRCVGAELGLDCPGRDYPNICAGTDRYAMYKVGPVLSVSHGMGIPSISIMLH
ELIKLLYYARCSNVTIIRIGTSGGIGLEPGTVVITEQAVDTCFKAEFEQIVLGKRVIRKT
DLNKKLVQELLLCSAELSEFTTVVGNTMCTLDFYEGQGRLDGALCSYTEKDKQAYLEAAY
AAGVRNIEMESSVFAAMCSACGLQAAVVCVTLLNRLEGDQISSPRNVLSEYQQRPQRLVS
YFIKKKLSKA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011758|Uridine phosphorylase 1 (UPP1)
ATGGCGGCCACGGGAGCCAATGCAGAGAAAGCTGAAAGTCACAATGATTGCCCCGTCAGA
CTTTTAAATCCAAACATAGCAAAAATGAAAGAAGATATTCTCTATCATTTCAATCTCACC
ACTAGCAGACACAATTTCCCAGCCTTGTTTGGAGATGTGAAGTTTGTGTGTGTTGGTGGA
AGCCCCTCCCGGATGAAAGCCTTCATCAGGTGCGTTGGTGCAGAGCTGGGCCTTGACTGC
CCAGGTAGAGACTATCCCAACATCTGTGCGGGAACTGACCGCTATGCCATGTATAAAGTA
GGACCGGTGCTGTCTGTCAGTCATGGTATGGGCATTCCTTCTATCTCAATCATGTTGCAT
GAGCTCATAAAGCTGCTGTACTATGCCCGGTGCTCCAACGTCACTATCATCCGCATTGGC
ACTTCTGGTGGGATAGGTCTGGAGCCCGGCACTGTGGTCATAACAGAGCAGGCAGTGGAT
ACCTGCTTCAAGGCAGAGTTTGAGCAGATTGTCCTGGGGAAGCGGGTCATCCGGAAAACG
GACCTTAACAAGAAGCTGGTGCAGGAGCTGTTGCTGTGTTCTGCAGAGCTGAGCGAGTTC
ACCACAGTGGTGGGGAACACCATGTGCACCTTGGACTTCTATGAAGGGCAAGGCCGTCTG
GATGGGGCTCTCTGCTCCTACACGGAGAAGGACAAGCAGGCGTATCTGGAGGCAGCCTAT
GCAGCCGGCGTCCGCAATATCGAGATGGAGTCCTCGGTGTTTGCCGCCATGTGCAGCGCC
TGCGGCCTCCAAGCGGCCGTGGTGTGTGTCACCCTCCTGAACCGCCTGGAAGGGGACCAG
ATCAGCAGCCCTCGCAATGTGCTCAGCGAGTACCAGCAGAGGCCGCAGCGGCTGGTGAGC
TACTTCATCAAGAAGAAACTGAGCAAGGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01048</identifier>
            <name>PNP_UDP_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>uridine phosphorylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to glucose starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleotide catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleoside catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleoside salvage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>UMP salvage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>uridine catabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="4">
      <id>BE0002457</id>
      <name>Uridine phosphorylase 2</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16613</ref-id>
            <pubmed-id>16720348</pubmed-id>
            <citation>Yan R, Wan L, Pizzorno G, Cao D: Uridine phosphorylase in breast cancer: a new prognostic factor? Front Biosci. 2006 Sep 1;11:2759-66.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O95045" source="Swiss-Prot">
        <name>Uridine phosphorylase 2</name>
        <general-function>Uridine phosphorylase activity</general-function>
        <specific-function>Catalyzes the reversible phosphorylytic cleavage of uridine and deoxyuridine to uracil and ribose- or deoxyribose-1-phosphate. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis. Shows substrate specificity and accept uridine, deoxyuridine, and thymidine as well as the two pyrimidine nucleoside analogs 5-fluorouridine and 5-fluoro-2(')-deoxyuridine as substrates.</specific-function>
        <gene-name>UPP2</gene-name>
        <locus>2q24.1</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.66</theoretical-pi>
        <molecular-weight>35526.93</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:23061</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>UPP2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AY225131</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O95045</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>UPP2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.2.3</synonym>
          <synonym>UPase 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004825|Uridine phosphorylase 2
MASVIPASNRSMRSDRNTYVGKRFVHVKNPYLDLMDEDILYHLDLGTKTHNLPAMFGDVK
FVCVGGSPNRMKAFALFMHKELGFEEAEEDIKDICAGTDRYCMYKTGPVLAISHGMGIPS
ISIMLHELIKLLHHARCCDVTIIRIGTSGGIGIAPGTVVITDIAVDSFFKPRFEQVILDN
IVTRSTELDKELSEELFNCSKEIPNFPTLVGHTMCTYDFYEGQGRLDGALCSFSREKKLD
YLKRAFKAGVRNIEMESTVFAAMCGLCGLKAAVVCVTLLDRLDCDQINLPHDVLVEYQQR
PQLLISNFIRRRLGLCD</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016797|Uridine phosphorylase 2 (UPP2)
ATGCTGGCCCCAGGCTGTGAGTTGGACCCAGACCAAGAAGTGGTGAGGACAAGGCCTGAA
GATGTGCCTGCTTCCCCTTCAACTTCCACCATGATTGTAAGTGTCCTGAGGCCTCCCAGC
CATGCTTCCTGTACAGCCTGTGGAACTGTGACTTTTCACATAGTAGAGAGAATGGCTTCA
GTTATACCTGCCTCCAATAGGTCCATGAGATCTGACAGGAATACATATGTTGGAAAAAGG
TTTGTTCACGTTAAAAATCCTTACTTGGATTTGATGGATGAAGACATTCTCTATCACTTG
GATTTGGGAACAAAAACACACAACCTACCAGCAATGTTTGGAGATGTAAAGTTTGTCTGT
GTCGGTGGGAGCCCCAACAGAATGAAAGCATTTGCACTGTTTATGCACAAGGAGCTCGGG
TTTGAGGAAGCTGAAGAAGACATAAAAGACATCTGTGCTGGGACAGACAGATACTGTATG
TACAAAACCGGGCCTGTGCTCGCCATCAGTCACGGCATGGGCATCCCCTCCATTTCTATT
ATGCTTCATGAACTCATCAAATTACTCCACCATGCACGGTGCTGCGATGTCACCATTATT
AGAATCGGTACATCAGGGGGAATAGGGATTGCACCAGGGACTGTTGTAATAACGGATATA
GCTGTAGACTCCTTCTTTAAGCCCCGGTTTGAACAGGTCATTTTGGACAACATTGTCACC
CGAAGTACTGAACTGGACAAAGAACTGTCTGAAGAACTGTTCAACTGTAGCAAAGAAATC
CCCAACTTCCCAACCCTCGTTGGACATACAATGTGTACCTATGATTTTTATGAAGGCCAA
GGCCGACTAGATGGAGCACTGTGCTCCTTTTCCAGAGAAAAAAAGTTAGACTACTTGAAG
AGAGCATTTAAAGCTGGTGTCAGGAATATTGAAATGGAATCTACAGTGTTTGCAGCTATG
TGTGGACTCTGTGGTCTAAAAGCTGCTGTGGTCTGTGTGACACTTCTCGACAGACTCGAC
TGTGATCAGATCAACTTGCCTCATGATGTCCTGGTGGAGTACCAGCAACGGCCTCAGCTC
CTAATCTCCAACTTCATCAGACGGCGGCTTGGACTTTGTGACTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01048</identifier>
            <name>PNP_UDP_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>type III intermediate filament</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>uridine phosphorylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleoside metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleotide catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleoside catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleoside salvage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>UMP salvage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>uridine metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="7">
      <id>BE0003336</id>
      <name>Cytochrome P450 2A6</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A33221</ref-id>
            <pubmed-id>25505563</pubmed-id>
            <citation>Yamamiya I, Yoshisue K, Ishii Y, Yamada H, Yoshida K: Enantioselectivity in the cytochrome P450-dependent conversion of tegafur to 5-fluorouracil in human liver microsomes. Pharmacol Res Perspect. 2013 Oct;1(1):e00009. doi: 10.1002/prp2.9. Epub 2013 Oct 23.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P11509" source="Swiss-Prot">
        <name>Cytochrome P450 2A6</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.</specific-function>
        <gene-name>CYP2A6</gene-name>
        <locus>19q13.2</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.69</theoretical-pi>
        <molecular-weight>56501.005</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2610</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2A6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X13897</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1321</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11509</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2A6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,4-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Coumarin 7-hydroxylase</synonym>
          <synonym>CYP2A3</synonym>
          <synonym>CYPIIA6</synonym>
          <synonym>Cytochrome P450 IIA3</synonym>
          <synonym>Cytochrome P450(I)</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037226|Cytochrome P450 2A6
MLASGMLLVALLVCLTVMVLMSVWQQRKSKGKLPPGPTPLPFIGNYLQLNTEQMYNSLMK
ISERYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVVFSN
GERAKQLRRFSIATLRDFGVGKRGIEERIQEEAGFLIDALRGTGGANIDPTFFLSRTVSN
VISSIVFGDRFDYKDKEFLSLLRMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFQL
LQGLEDFIAKKVEHNQRTLDPNSPRDFIDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFI
GGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYMEAVIHEIQ
RFGDVIPMSLARRVKKDTKFRDFFLPKGTEVFPMLGSVLRDPSFFSNPQDFNPQHFLNEK
GQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVGF
ATIPRNYTMSFLPR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021356|Cytochrome P450 2A6 (CYP2A6)
ATGCTGGCCTCAGGGATGCTTCTGGTGGCCTTGCTGGTCTGCCTGACTGTAATGGTCTTG
ATGTCTGTTTGGCAGCAGAGGAAGAGCAAGGGGAAGCTGCCTCCGGGACCCACCCCATTG
CCCTTCATTGGAAACTACCTGCAGCTGAACACAGAGCAGATGTACAACTCCCTCATGAAG
ATCAGTGAGCGCTATGGCCCCGTGTTCACCATTCACTTGGGGCCCCGGCGGGTCGTGGTG
CTGTGTGGACATGATGCCGTCAGGGAGGCTCTGGTGGACCAGGCTGAGGAGTTCAGCGGG
CGAGGCGAGCAAGCCACCTTCGACTGGGTCTTCAAAGGCTATGGCGTGGTATTCAGCAAC
GGGGAGCGCGCCAAGCAGCTCCGGCGCTTCTCCATCGCCACCCTGCGGGACTTCGGGGTG
GGCAAGCGAGGCATCGAGGAGCGCATCCAGGAGGAGGCGGGCTTCCTCATCGACGCCCTC
CGGGGCACTGGCGGCGCCAATATCGATCCCACCTTCTTCCTGAGCCGCACAGTCTCCAAT
GTCATCAGCTCCATTGTCTTTGGGGACCGCTTTGACTATAAGGACAAAGAGTTCCTGTCA
CTGTTGCGCATGATGCTAGGAATCTTCCAGTTCACGTCAACCTCCACGGGGCAGCTCTAT
GAGATGTTCTCTTCGGTGATGAAACACCTGCCAGGACCACAGCAACAGGCCTTTCAGTTG
CTGCAAGGGCTGGAGGACTTCATAGCCAAGAAGGTGGAGCACAACCAGCGCACGCTGGAT
CCCAATTCCCCACGGGACTTCATTGACTCCTTTCTCATCCGCATGCAGGAGGAGGAGAAG
AACCCCAACACGGAGTTCTACTTGAAAAACCTGGTGATGACCACGTTGAACCTCTTCATT
GGGGGCACCGAGACCGTCAGCACCACCCTGCGCTATGGCTTCTTGCTGCTCATGAAGCAC
CCAGAGGTGGAGGCCAAGGTCCATGAGGAGATTGACAGAGTGATCGGCAAGAACCGGCAG
CCCAAGTTTGAGGACCGGGCCAAGATGCCCTACATGGAGGCAGTGATCCACGAGATCCAA
AGATTTGGAGACGTGATCCCCATGAGTTTGGCCCGCAGAGTCAAAAAGGACACCAAGTTT
CGGGATTTCTTCCTCCCTAAGGGCACCGAAGTGTACCCTATGCTGGGCTCTGTGCTGAGA
GACCCCAGTTTCTTCTCCAACCCCCAGGACTTCAATCCCCAGCACTTCCTGAATGAGAAG
GGGCAGTTTAAGAAGAGTGATGCTTTTGTGCCCTTTTCCATCGGAAAGCGGAACTGTTTC
GGAGAAGGCCTGGCCAGAATGGAGCTCTTTCTCTTCTTCACCACCGTCATGCAGAACTTC
CGCCTCAAGTCCTCCCAGTCACCTAAGGACATTGACGTGTCCCCCAAACACGTGGGCTTT
GCCACGATCCCACGAAACTACACCATGAGCTTCCTGCCCCGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic microtubule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>coumarin 7-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coumarin catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coumarin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="8">
      <id>BE0002887</id>
      <name>Cytochrome P450 2C8</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A37953</ref-id>
            <pubmed-id>11095583</pubmed-id>
            <citation>Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T: Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10632" source="Swiss-Prot">
        <name>Cytochrome P450 2C8</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti-cancer drug paclitaxel (taxol).</specific-function>
        <gene-name>CYP2C8</gene-name>
        <locus>10q23.33</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.62</theoretical-pi>
        <molecular-weight>55824.275</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2622</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2C8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M17397</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1325</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10632</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2C8_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIIC8</synonym>
          <synonym>Cytochrome P450 form 1</synonym>
          <synonym>Cytochrome P450 IIC2</synonym>
          <synonym>Cytochrome P450 MP-12</synonym>
          <synonym>Cytochrome P450 MP-20</synonym>
          <synonym>S-mephenytoin 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005650|Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021338|Cytochrome P450 2C8 (CYP2C8)
ATGGAACCTTTTGTGGTCCTGGTGCTGTGTCTCTCTTTTATGCTTCTCTTTTCACTCTGG
AGACAGAGCTGTAGGAGAAGGAAGCTCCCTCCTGGCCCCACTCCTCTTCCTATTATTGGA
AATATGCTACAGATAGATGTTAAGGACATCTGCAAATCTTTCACCAATTTCTCAAAAGTC
TATGGTCCTGTGTTCACCGTGTATTTTGGCATGAATCCCATAGTGGTGTTTCATGGATAT
GAGGCAGTGAAGGAAGCCCTGATTGATAATGGAGAGGAGTTTTCTGGAAGAGGCAATTCC
CCAATATCTCAAAGAATTACTAAAGGACTTGGAATCATTTCCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCACAACCTTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCTCACTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
GTTGTTTTCCAGAAACGATTTGATTATAAAGATCAGAATTTTCTCACCCTGATGAAAAGA
TTCAATGAAAACTTCAGGATTCTGAACTCCCCATGGATCCAGGTCTGCAATAATTTCCCT
CTACTCATTGATTGTTTCCCAGGAACTCACAACAAAGTGCTTAAAAATGTTGCTCTTACA
CGAAGTTACATTAGGGAGAAAGTAAAAGAACACCAAGCATCACTGGATGTTAACAATCCT
CGGGACTTTATCGATTGCTTCCTGATCAAAATGGAGCAGGAAAAGGACAACCAAAAGTCA
GAATTCAATATTGAAAACTTGGTTGGCACTGTAGCTGATCTATTTGTTGCTGGAACAGAG
ACAACAAGCACCACTCTGAGATATGGACTCCTGCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGATCATGTAATTGGCAGACACAGGAGCCCCTGCATGCAG
GATAGGAGCCACATGCCTTACACTGATGCTGTAGTGCACGAGATCCAGAGATACAGTGAC
CTTGTCCCCACCGGTGTGCCCCATGCAGTGACCACTGATACTAAGTTCAGAAACTACCTC
ATCCCCAAGGGCACAACCATAATGGCATTACTGACTTCCGTGCTACATGATGACAAAGAA
TTTCCTAATCCAAATATCTTTGACCCTGGCCACTTTCTAGATAAGAATGGCAACTTTAAG
AAAAGTGACTACTTCATGCCTTTCTCAGCAGGAAAACGAATTTGTGCAGGAGAAGGACTT
GCCCGCATGGAGCTATTTTTATTTCTAACCACAATTTTACAGAACTTTAACCTGAAATCT
GTTGATGATTTAAAGAACCTCAATACTACTGCAGTTACCAAAGGGATTGTTTCTCTGCCA
CCCTCATACCAGATCTGCTTCATCCCTGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="9">
      <id>BE0002176</id>
      <name>Methylenetetrahydrofolate reductase</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15123</ref-id>
            <pubmed-id>21332317</pubmed-id>
            <citation>Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S: 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65. doi: 10.2217/pgs.10.167.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P42898" source="Swiss-Prot">
        <name>Methylenetetrahydrofolate reductase</name>
        <general-function>Protein complex binding</general-function>
        <specific-function>Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine.</specific-function>
        <gene-name>MTHFR</gene-name>
        <locus>1p36.3</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.0</theoretical-pi>
        <molecular-weight>74595.895</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7436</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>MTHFR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U09806</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>6139053</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P42898</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MTHR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.5.1.20</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004270|Methylenetetrahydrofolate reductase
MVNEARGNSSLNPCLEGSASSGSESSKDSSRCSTPGLDPERHERLREKMRRRLESGDKWF
SLEFFPPRTAEGAVNLISRFDRMAAGGPLYIDVTWHPAGDPGSDKETSSMMIASTAVNYC
GLETILHMTCCRQRLEEITGHLHKAKQLGLKNIMALRGDPIGDQWEEEEGGFNYAVDLVK
HIRSEFGDYFDICVAGYPKGHPEAGSFEADLKHLKEKVSAGADFIITQLFFEADTFFRFV
KACTDMGITCPIVPGIFPIQGYHSLRQLVKLSKLEVPQEIKDVIEPIKDNDAAIRNYGIE
LAVSLCQELLASGLVPGLHFYTLNREMATTEVLKRLGMWTEDPRRPLPWALSAHPKRREE
DVRPIFWASRPKSYIYRTQEWDEFPNGRWGNSSSPAFGELKDYYLFYLKSKSPKEELLKM
WGEELTSEESVFEVFVLYLSGEPNRNGHKVTCLPWNDEPLAAETSLLKEELLRVNRQGIL
TINSQPNINGKPSSDPIVGWGPSGGYVFQKAYLEFFTSRETAEALLQVLKKYELRVNYHL
VNVKGENITNAPELQPNAVTWGIFPGREIIQPTVVDPVSFMFWKDEAFALWIERWGKLYE
EESPSRTIIQYIHDNYFLVNLVDNDFPLDNCLWQVVEDTLELLNRPTQNARETEAP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020597|Methylenetetrahydrofolate reductase (MTHFR)
ATGGTGAACGAAGCCAGAGGAAACAGCAGCCTCAACCCCTGCTTGGAGGGCAGTGCCAGC
AGTGGCAGTGAGAGCTCCAAAGATAGTTCGAGATGTTCCACCCCGGGCCTGGACCCCGAG
CGGCATGAGAGACTCCGGGAGAAGATGAGGCGGCGATTGGAATCTGGTGACAAGTGGTTC
TCCCTGGAATTCTTCCCTCCTCGAACTGCTGAGGGAGCTGTCAATCTCATCTCAAGGTTT
GACCGGATGGCAGCAGGTGGCCCCCTCTACATAGACGTGACCTGGCACCCAGCAGGTGAC
CCTGGCTCAGACAAGGAGACCTCCTCCATGATGATCGCCAGCACCGCCGTGAACTACTGT
GGCCTGGAGACCATCCTGCACATGACCTGCTGCCGTCAGCGCCTGGAGGAGATCACGGGC
CATCTGCACAAAGCTAAGCAGCTGGGCCTGAAGAACATCATGGCGCTGCGGGGAGACCCA
ATAGGTGACCAGTGGGAAGAGGAGGAGGGAGGCTTCAACTACGCAGTGGACCTGGTGAAG
CACATCCGAAGTGAGTTTGGTGACTACTTTGACATCTGTGTGGCAGGTTACCCCAAAGGC
CACCCCGAAGCAGGGAGCTTTGAGGCTGACCTGAAGCACTTGAAGGAGAAGGTGTCTGCG
GGAGCCGATTTCATCATCACGCAGCTTTTCTTTGAGGCTGACACATTCTTCCGCTTTGTG
AAGGCATGCACCGACATGGGCATCACTTGCCCCATCGTCCCCGGGATCTTTCCCATCCAG
GGCTACCACTCCCTTCGGCAGCTTGTGAAGCTGTCCAAGCTGGAGGTGCCACAGGAGATC
AAGGACGTGATTGAGCCAATCAAAGACAACGATGCTGCCATCCGCAACTATGGCATCGAG
CTGGCCGTGAGCCTGTGCCAGGAGCTTCTGGCCAGTGGCTTGGTGCCAGGCCTCCACTTC
TACACCCTCAACCGCGAGATGGCTACCACAGAGGTGCTGAAGCGCCTGGGGATGTGGACT
GAGGACCCCAGGCGTCCCCTACCCTGGGCTCTCAGCGCCCACCCCAAGCGCCGAGAGGAA
GATGTACGTCCCATCTTCTGGGCCTCCAGACCAAAGAGTTACATCTACCGTACCCAGGAG
TGGGACGAGTTCCCTAACGGCCGCTGGGGCAATTCCTCTTCCCCTGCCTTTGGGGAGCTG
AAGGACTACTACCTCTTCTACCTGAAGAGCAAGTCCCCCAAGGAGGAGCTGCTGAAGATG
TGGGGGGAGGAGCTGACCAGTGAAGAAAGTGTCTTTGAAGTCTTCGTTCTTTACCTCTCG
GGAGAACCAAACCGGAATGGTCACAAAGTGACTTGCCTGCCCTGGAACGATGAGCCCCTG
GCGGCTGAGACCAGCCTGCTGAAGGAGGAGCTGCTGCGGGTGAACCGCCAGGGCATCCTC
ACCATCAACTCACAGCCCAACATCAACGGGAAGCCGTCCTCCGACCCCATCGTGGGCTGG
GGCCCCAGCGGGGGCTATGTCTTCCAGAAGGCCTACTTAGAGTTTTTCACTTCCCGCGAG
ACAGCGGAAGCACTTCTGCAAGTGCTGAAGAAGTACGAGCTCCGGGTTAATTACCACCTT
GTCAATGTGAAGGGTGAAAACATCACCAATGCCCCTGAACTGCAGCCGAATGCTGTCACT
TGGGGCATCTTCCCTGGGCGAGAGATCATCCAGCCCACCGTAGTGGATCCCGTCAGCTTC
ATGTTCTGGAAGGACGAGGCCTTTGCCCTGTGGATTGAGCGGTGGGGAAAGCTGTATGAG
GAGGAGTCCCCGTCCCGCACCATCATCCAGTACATCCACGACAACTACTTCCTGGTCAAC
CTGGTGGACAATGACTTCCCACTGGACAACTGCCTCTGGCAGGTGGTGGAAGACACATTG
GAGCTTCTCAACAGGCCCACCCAGAATGCGAGAGAAACGGAGGCTCCATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02219</identifier>
            <name>MTHFR</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>flavin adenine dinucleotide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>methylenetetrahydrofolate reductase (NAD(P)H) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>modified amino acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NADP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein complex binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood circulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular amino acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>folic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterochromatin maintenance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>homocysteine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>methionine biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>methionine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of histone methylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to folic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to interleukin-1</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin B2</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>S-adenosylmethionine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tetrahydrofolate interconversion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>water-soluble vitamin metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="9">
      <id>BE0000324</id>
      <name>Thymidylate synthase</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15123</ref-id>
            <pubmed-id>21332317</pubmed-id>
            <citation>Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S: 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65. doi: 10.2217/pgs.10.167.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P04818" source="Swiss-Prot">
        <name>Thymidylate synthase</name>
        <general-function>Thymidylate synthase activity</general-function>
        <specific-function>Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.</specific-function>
        <gene-name>TYMS</gene-name>
        <locus>18p11.32</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.0</theoretical-pi>
        <molecular-weight>35715.65</molecular-weight>
        <chromosome-location>18</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12441</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>TYMS</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X02308</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>37479</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2642</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04818</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TYSY_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.1.1.45</synonym>
          <synonym>TS</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036991|Thymidylate synthase
MPVAGSELPRRPLPPAAQERDAEPRPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFG
MQARYSLRDEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDS
LGFSTREEGDLGPVYGFQWRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMC
AWNPRDLPLMALPPCHALCQFYVVNSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHI
TGLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRPFPKLRILRKVEKIDDFKAEDFQIEG
YNPHPTIKMEMAV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010247|Thymidylate synthase (TYMS)
ATGCCTGTGGCCGGCTCGGAGCTGCCGCGCCGGCCCTTGCCCCCCGCCGCACAGGAGCGG
GACGCCGAGCCGCGTCCGCCGCACGGGGAGCTGCAGTACCTGGGGCAGATCCAACACATC
CTCCGCTGCGGCGTCAGGAAGGACGACCGCACGGGCACCGGCACCCTGTCGGTATTCGGC
ATGCAGGCGCGCTACAGCCTGAGAGATGAATTCCCTCTGCTGACAACCAAACGTGTGTTC
TGGAAGGGTGTTTTGGAGGAGTTGCTGTGGTTTATCAAGGGATCCACAAATGCTAAAGAG
CTGTCTTCCAAGGGAGTGAAAATCTGGGATGCCAATGGATCCCGAGACTTTTTGGACAGC
CTGGGATTCTCCACCAGAGAAGAAGGGGACTTGGGCCCAGTTTATGGCTTCCAGTGGAGG
CATTTTGGGGCAGAATACAGAGATATGGAATCAGATTATTCAGGACAGGGAGTTGACCAA
CTGCAAAGAGTGATTGACACCATCAAAACCAACCCTGACGACAGAAGAATCATCATGTGC
GCTTGGAATCCAAGAGATCTTCCTCTGATGGCGCTGCCTCCATGCCATGCCCTCTGCCAG
TTCTATGTGGTGAACAGTGAGCTGTCCTGCCAGCTGTACCAGAGATCGGGAGACATGGGC
CTCGGTGTGCCTTTCAACATCGCCAGCTACGCCCTGCTCACGTACATGATTGCGCACATC
ACGGGCCTGAAGCCAGGTGACTTTATACACACTTTGGGAGATGCACATATTTACCTGAAT
CACATCGAGCCACTGAAAATTCAGCTTCAGCGAGAACCCAGACCTTTCCCAAAGCTCAGG
ATTCTTCGAAAAGTTGAGAAAATTGATGACTTCAAAGCTGAAGACTTTCAGATTGAAGGG
TACAATCCGCATCCAACTATTAAAATGGAAATGGCTGTTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00303</identifier>
            <name>Thymidylat_synt</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial inner membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleolus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cofactor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>folic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>mRNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nucleotide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thymidylate synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cartilage development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>deoxyribonucleoside monophosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>developmental growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dTMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dTTP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dUMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immortalization of host cell by virus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intestinal epithelial cell maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organ regeneration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleoside biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription involved in G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cytokine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to folic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucocorticoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to organophosphorus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to progesterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin A</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tetrahydrofolate interconversion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>uracil metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="10">
      <id>BE0004473</id>
      <name>Uridine 5'-monophosphate synthase</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L172</ref-id>
            <title>Link</title>
            <url>https://www.pharmgkb.org/pathway/PA150653776</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P11172" source="Swiss-Prot">
        <name>Uridine 5'-monophosphate synthase</name>
        <general-function>Orotidine-5'-phosphate decarboxylase activity</general-function>
        <specific-function/>
        <gene-name>UMPS</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>52221.075</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12563</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11172</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>UMPS_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>UMP synthase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009394|Uridine 5'-monophosphate synthase
MAVARAALGPLVTGLYDVQAFKFGDFVLKSGLSSPIYIDLRGIVSRPRLLSQVADILFQT
AQNAGISFDTVCGVPYTALPLATVICSTNQIPMLIRRKETKDYGTKRLVEGTINPGETCL
IIEDVVTSGSSVLETVEVLQKEGLKVTDAIVLLDREQGGKDKLQAHGIRLHSVCTLSKML
EILEQQKKVDAETVGRVKRFIQENVFVAANHNGSPLSIKEAPKELSFGARAELPRIHPVA
SKLLRLMQKKETNLCLSADVSLARELLQLADALGPSICMLKTHVDILNDFTLDVMKELIT
LAKCHEFLIFEDRKFADIGNTVKKQYEGGIFKIASWADLVNAHVVPGSGVVKGLQEVGLP
LHRGCLLIAEMSSTGSLATGDYTRAAVRMAEEHSEFVVGFISGSRVSMKPEFLHLTPGVQ
LEAGGDNLGQQYNSPQEVIGKRGSDIIIVGRGIISAADRLEAAEMYRKAAWEAYLSRLGV
</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020771|Uridine 5'-monophosphate synthase (UMPS)
ATGGCGGTCGCTCGTGCAGCTTTGGGGCCATTGGTGACGGGTCTGTACGACGTGCAGGCT
TTCAAGTTTGGGGACTTCGTGCTGAAGAGCGGGCTTTCCTCCCCCATCTACATCGATCTG
CGGGGCATCGTGTCTCGACCGCGTCTTCTGAGTCAGGTTGCAGATATTTTATTCCAAACT
GCCCAAAATGCAGGCATCAGTTTTGACACCGTGTGTGGAGTGCCTTATACAGCTTTGCCA
TTGGCTACAGTTATCTGTTCAACCAATCAAATTCCAATGCTTATTAGAAGGAAAGAAACA
AAGGATTATGGAACTAAGCGTCTTGTAGAAGGAACTATTAATCCAGGAGAAACCTGTTTA
ATCATTGAAGATGTTGTCACCAGTGGATCTAGTGTTTTGGAAACTGTTGAGGTTCTTCAG
AAGGAGGGCTTGAAGGTCACTGATGCCATAGTGCTGTTGGACAGAGAGCAGGGAGGCAAG
GACAAGTTGCAGGCGCACGGGATCCGCCTCCACTCAGTGTGTACATTGTCCAAAATGCTG
GAGATTCTCGAGCAGCAGAAAAAAGTTGATGCTGAGACAGTTGGGAGAGTGAAGAGGTTT
ATTCAGGAGAATGTCTTTGTGGCAGCGAATCATAATGGTTCTCCCCTTTCTATAAAGGAA
GCACCCAAAGAACTCAGCTTCGGTGCACGTGCAGAGCTGCCCAGGATCCACCCAGTTGCA
TCGAAGCTTCTCAGGCTTATGCAAAAGAAGGAGACCAATCTGTGTCTATCTGCTGATGTT
TCACTGGCCAGAGAGCTGTTGCAGCTAGCAGATGCTTTAGGACCTAGTATCTGCATGCTG
AAGACTCATGTAGATATTTTGAATGATTTTACTCTGGATGTGATGAAGGAGTTGATAACT
CTGGCAAAATGCCATGAGTTCTTGATATTTGAAGACCGGAAGTTTGCAGATATAGGAAAC
ACAGTGAAAAAGCAGTATGAAGGAGGTATCTTTAAAATAGCTTCCTGGGCAGATCTAGTA
AATGCTCACGTGGTGCCAGGCTCAGGAGTTGTGAAAGGCCTGCAAGAAGTGGGCCTGCCT
TTGCATCGGGGGTGCCTCCTTATTGCGGAAATGAGCTCCACCGGCTCCCTGGCCACTGGG
GACTACACTAGAGCAGCGGTTAGAATGGCTGAGGAGCACTCTGAATTTGTTGTTGGTTTT
ATTTCTGGCTCCCGAGTAAGCATGAAACCAGAATTTCTTCACTTGACTCCAGGAGTTCAG
TTGGAAGCAGGAGGAGATAATCTTGGCCAACAGTACAATAGCCCACAAGAAGTTATTGGC
AAACGAGGTTCCGATATCATCATTGTAGGTCGTGGCATAATCTCAGCAGCTGATCGTCTG
GAAGCAGCAGAGATGTACAGAAAAGCTGCTTGGGAAGCGTATTTGAGTAGACTTGGTGTT
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00156</identifier>
            <name>Pribosyltran</name>
          </pfam>
          <pfam>
            <identifier>PF00215</identifier>
            <name>OMPdecase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>orotate phosphoribosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>orotidine-5'-phosphate decarboxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>'de novo' pyrimidine nucleobase biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>'de novo' UMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>female pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lactation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pyrimidine nucleoside biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>UMP biosynthetic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="11">
      <id>BE0000374</id>
      <name>Amidophosphoribosyltransferase</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L172</ref-id>
            <title>Link</title>
            <url>https://www.pharmgkb.org/pathway/PA150653776</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q06203" source="Swiss-Prot">
        <name>Amidophosphoribosyltransferase</name>
        <general-function>Metal ion binding</general-function>
        <specific-function/>
        <gene-name>PPAT</gene-name>
        <locus>4q12</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.74</theoretical-pi>
        <molecular-weight>57398.52</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9238</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PPAT</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D13757</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>219459</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q06203</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PUR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.2.14</synonym>
          <synonym>ATase</synonym>
          <synonym>Glutamine phosphoribosylpyrophosphate amidotransferase</synonym>
          <synonym>GPAT</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010265|Amidophosphoribosyltransferase
MELEELGIREECGVFGCIASGEWPTQLDVPHVITLGLVGLQHRGQESAGIVTSDGSSVPT
FKSHKGMGLVNHVFTEDNLKKLYVSNLGIGHTRYATTGKCELENCQPFVVETLHGKIAVA
HNGELVNAARLRKKLLRHGIGLSTSSDSEMITQLLAYTPPQEQDDTPDWVARIKNLMKEA
PTAYSLLIMHRDVIYAVRDPYGNRPLCIGRLIPVSDINDKEKKTSETEGWVVSSESCSFL
SIGARYYREVLPGEIVEISRHNVQTLDIISRSEGNPVAFCIFEYVYFARPDSMFEDQMVY
TVRYRCGQQLAIEAPVDADLVSTVPESATPAALAYAGKCGLPYVEVLCKNRYVGRTFIQP
NMRLRQLGVAKKFGVLSDNFKGKRIVLVDDSIVRGNTISPIIKLLKESGAKEVHIRVASP
PIKYPCFMGINIPTKEELIANKPEFDHLAEYLGANSVVYLSVEGLVSSVQEGIKFKKQKE
KKHDIMIQENGNGLECFEKSGHCTACLTGKYPVELEW</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010266|Amidophosphoribosyltransferase (PPAT)
ATGGAGCTGGAGGAGTTGGGGATCCGAGAGGAATGTGGCGTGTTCGGGTGCATCGCCTCA
GGAGAGTGGCCCACGCAGCTGGATGTACCGCATGTGATCACTCTGGGACTCGTGGGGCTG
CAGCACCGGGGTCAGGAGAGTGCTGGTATTGTGACTAGTGATGGGAGTTCGGTGCCAACA
TTCAAATCACACAAGGGAATGGGTCTTGTAAATCACGTCTTTACTGAAGACAATTTGAAA
AAATTATATGTTTCAAATCTTGGAATTGGACACACCAGGTATGCCACCACAGGAAAATGT
GAACTAGAAAATTGTCAGCCCTTCGTTGTTGAAACACTTCATGGGAAGATAGCTGTGGCA
CATAATGGCGAATTGGTAAATGCTGCTCGATTAAGGAAAAAGCTTCTGCGTCATGGTATT
GGTCTGTCTACAAGTTCTGATAGTGAAATGATTACCCAGTTACTGGCGTATACCCCTCCT
CAGGAACAAGATGACACCCCAGACTGGGTAGCCAGGATTAAAAACTTGATGAAGGAAGCA
CCCACAGCATACTCCCTGCTTATAATGCACAGAGATGTTATTTATGCAGTACGAGATCCT
TATGGAAATCGTCCCTTATGCATTGGTCGTCTTATTCCAGTGTCTGATATAAATGACAAA
GAGAAAAAAACATCAGAAACAGAAGGATGGGTGGTGTCTTCAGAATCTTGTAGCTTCTTA
TCTATTGGTGCAAGATATTACCGTGAAGTCTTGCCTGGAGAAATTGTGGAAATATCCAGA
CACAATGTCCAAACTCTTGATATTATATCAAGGTCTGAAGGAAACCCAGTGGCTTTTTGT
ATCTTTGAATATGTTTATTTTGCAAGACCAGACAGTATGTTCGAAGACCAAATGGTTTAT
ACAGTAAGATACCGTTGTGGCCAGCAGCTAGCGATTGAAGCACCTGTGGATGCAGATTTG
GTTAGCACTGTTCCAGAATCTGCTACGCCTGCTGCTCTTGCTTACGCAGGAAAGTGTGGA
CTTCCATATGTGGAGGTGCTGTGTAAAAACCGGTATGTAGGGAGAACCTTCATTCAGCCA
AACATGAGGTTAAGACAACTTGGTGTTGCAAAAAAATTTGGAGTATTGTCAGACAACTTT
AAAGGCAAAAGAATTGTTCTTGTAGATGATTCAATTGTCAGAGGCAATACCATCTCACCT
ATAATAAAACTGCTCAAAGAATCTGGTGCAAAAGAGGTACACATTCGAGTAGCTTCACCA
CCAATTAAATATCCATGCTTCATGGGAATAAACATTCCTACAAAAGAAGAGCTCATTGCC
AATAAACCAGAATTTGATCACCTTGCAGAATATCTAGGAGCAAACAGTGTTGTGTATCTG
TCAGTAGAAGGACTGGTTTCATCTGTACAAGAAGGGATAAAGTTTAAAAAACAGAAAGAG
AAAAAGCACGATATTATGATCCAAGAAAATGGAAATGGTCTGGAATGTTTTGAAAAGAGT
GGTCATTGTACAGCTTGTCTCACTGGAAAATATCCTGTAGAATTAGAATGGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00156</identifier>
            <name>Pribosyltran</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>4 iron, 4 sulfur cluster binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>amidophosphoribosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>'de novo' IMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glutamine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>kidney development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lactation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maternal process involved in female pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleoside metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organ regeneration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homotetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine nucleobase biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine nucleotide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine ribonucleoside monophosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers>
    <carrier position="1">
      <id>BE0000530</id>
      <name>Serum albumin</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A15495</ref-id>
            <pubmed-id>15150801</pubmed-id>
            <citation>Sulkowska A, Bojko B, Rownicka J, Sulkowski W: Competition of drugs to serum albumin in combination therapy. Biopolymers. 2004 Jun 15;74(3):256-62.</citation>
          </article>
          <article>
            <ref-id>A15496</ref-id>
            <pubmed-id>8573632</pubmed-id>
            <citation>Bertucci C, Ascoli G, Uccello-Barretta G, Di Bari L, Salvadori P: The binding of 5-fluorouracil to native and modified human serum albumin: UV, CD, and 1H and 19F NMR investigation. J Pharm Biomed Anal. 1995 Aug;13(9):1087-93.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P02768" source="Swiss-Prot">
        <name>Serum albumin</name>
        <general-function>Toxic substance binding</general-function>
        <specific-function>Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.</specific-function>
        <gene-name>ALB</gene-name>
        <locus>4q11-q13</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>6.21</theoretical-pi>
        <molecular-weight>69365.94</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:399</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ALB</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>V00494</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>28590</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02768</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ALBU_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Serum albumin precursor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001058|Serum albumin
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
AASQAALGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010372|Serum albumin (ALB)
ATGAAGTGGGTAACCTTTATTTCCCTTCTTTTTCTCTTTAGCTCGGCTTATTCCAGGGGT
GTGTTTCGTCGAGATGCACACAAGAGTGAGGTTGCTCATCGGTTTAAAGATTTGGGAGAA
GAAAATTTCAAAGCCTTGGTGTTGATTGCCTTTGCTCAGTATCTTCAGCAGTGTCCATTT
GAAGATCATGTAAAATTAGTGAATGAAGTAACTGAATTTGCAAAAACATGTGTTGCTGAT
GAGTCAGCTGAAAATTGTGACAAATCACTTCATACCCTTTTTGGAGACAAATTATGCACA
GTTGCAACTCTTCGTGAAACCTATGGTGAAATGGCTGACTGCTGTGCAAAACAAGAACCT
GAGAGAAATGAATGCTTCTTGCAACACAAAGATGACAACCCAAACCTCCCCCGATTGGTG
AGACCAGAGGTTGATGTGATGTGCACTGCTTTTCATGACAATGAAGAGACATTTTTGAAA
AAATACTTATATGAAATTGCCAGAAGACATCCTTACTTTTATGCCCCGGAACTCCTTTTC
TTTGCTAAAAGGTATAAAGCTGCTTTTACAGAATGTTGCCAAGCTGCTGATAAAGCTGCC
TGCCTGTTGCCAAAGCTCGATGAACTTCGGGATGAAGGGAAGGCTTCGTCTGCCAAACAG
AGACTCAAGTGTGCCAGTCTCCAAAAATTTGGAGAAAGAGCTTTCAAAGCATGGGCAGTA
GCTCGCCTGAGCCAGAGATTTCCCAAAGCTGAGTTTGCAGAAGTTTCCAAGTTAGTGACA
GATCTTACCAAAGTCCACACGGAATGCTGCCATGGAGATCTGCTTGAATGTGCTGATGAC
AGGGCGGACCTTGCCAAGTATATCTGTGAAAATCAAGATTCGATCTCCAGTAAACTGAAG
GAATGCTGTGAAAAACCTCTGTTGGAAAAATCCCACTGCATTGCCGAAGTGGAAAATGAT
GAGATGCCTGCTGACTTGCCTTCATTAGCTGCTGATTTTGTTGAAAGTAAGGATGTTTGC
AAAAACTATGCTGAGGCAAAGGATGTCTTCCTGGGCATGTTTTTGTATGAATATGCAAGA
AGGCATCCTGATTACTCTGTCGTGCTGCTGCTGAGACTTGCCAAGACATATGAAACCACT
CTAGAGAAGTGCTGTGCCGCTGCAGATCCTCATGAATGCTATGCCAAAGTGTTCGATGAA
TTTAAACCTCTTGTGGAAGAGCCTCAGAATTTAATCAAACAAAATTGTGAGCTTTTTGAG
CAGCTTGGAGAGTACAAATTCCAGAATGCGCTATTAGTTCGTTACACCAAGAAAGTACCC
CAAGTGTCAACTCCAACTCTTGTAGAGGTCTCAAGAAACCTAGGAAAAGTGGGCAGCAAA
TGTTGTAAACATCCTGAAGCAAAAAGAATGCCCTGTGCAGAAGACTATCTATCCGTGGTC
CTGAACCAGTTATGTGTGTTGCATGAGAAAACGCCAGTAAGTGACAGAGTCACCAAATGC
TGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAAACA
TACGTTCCCAAAGAGTTTAATGCTGAAACATTCACCTTCCATGCAGATATATGCACACTT
TCTGAGAAGGAGAGACAAATCAAGAAACAAACTGCACTTGTTGAGCTCGTGAAACACAAG
CCCAAGGCAACAAAAGAGCAACTGAAAGCTGTTATGGATGATTTCGCAGCTTTTGTAGAG
AAGTGCTGCAAGGCTGACGATAAGGAGACCTGCTTTGCCGAGGAGGGTAAAAAACTTGTT
GCTGCAAGTCAAGCTGCCTTAGGCTTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00273</identifier>
            <name>Serum_albumin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myelin sheath</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>antioxidant activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chaperone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>copper ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fatty acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyridoxal phosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>toxic substance binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hemolysis by symbiont of host erythrocytes</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of mitochondrion location</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
    <carrier position="18">
      <id>BE0000537</id>
      <name>Thyroxine-binding globulin</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments>
          <attachment>
            <ref-id>F3799</ref-id>
            <title>CYTOMEL (liothyronine) FDA label</title>
            <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/799/original/fda.pdf?1551828936</url>
          </attachment>
        </attachments>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P05543" source="Swiss-Prot">
        <name>Thyroxine-binding globulin</name>
        <general-function>Serine-type endopeptidase inhibitor activity</general-function>
        <specific-function>Major thyroid hormone transport protein in serum.</specific-function>
        <gene-name>SERPINA7</gene-name>
        <locus>Xq22.2</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-20</signal-regions>
        <theoretical-pi>6.27</theoretical-pi>
        <molecular-weight>46324.12</molecular-weight>
        <chromosome-location>X</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11583</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SERPINA7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M14091</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>338697</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05543</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>THBG_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Serpin A7</synonym>
          <synonym>T4-binding globulin</synonym>
          <synonym>TBG</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016123|Thyroxine-binding globulin
MSPFLYLVLLVLGLHATIHCASPEGKVTACHSSQPNATLYKMSSINADFAFNLYRRFTVE
TPDKNIFFSPVSISAALVMLSFGACCSTQTEIVETLGFNLTDTPMVEIQHGFQHLICSLN
FPKKELELQIGNALFIGKHLKPLAKFLNDVKTLYETEVFSTDFSNISAAKQEINSHVEMQ
TKGKVVGLIQDLKPNTIMVLVNYIHFKAQWANPFDPSKTEDSSSFLIDKTTTVQVPMMHQ
MEQYYHLVDMELNCTVLQMDYSKNALALFVLPKEGQMESVEAAMSSKTLKKWNRLLQKGW
VDLFVPKFSISATYDLGATLLKMGIQHAYSENADFSGLTEDNGLKLSNAAHKAVLHIGEK
GTEAAAVPEVELSDQPENTFLHPIIQIDRSFMLLILERSTRSILFLGKVVNPTEA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016124|Thyroxine-binding globulin (SERPINA7)
ATGTCACCATTCCTGTATCTGGTTCTCTTGGTACTTGGGCTTCATGCTACAATCCACTGT
GCATCACCTGAAGGCAAAGTAACAGCCTGCCATTCATCCCAACCAAATGCCACTCTCTAC
AAGATGTCATCCATTAATGCTGACTTTGCATTCAATCTGTACCGGAGGTTCACTGTGGAG
ACCCCAGATAAGAACATCTTCTTTTCCCCTGTGAGCATTTCTGCAGCTTTGGTTATGCTT
TCCTTTGGGGCCTGCTGCAGCACCCAAACTGAGATTGTGGAGACCTTGGGGTTCAACCTC
ACAGACACTCCAATGGTAGAGATCCAGCATGGCTTCCAGCATCTGATCTGTTCACTGAAT
TTTCCAAAGAAGGAACTGGAATTGCAGATAGGAAATGCCCTCTTCATTGGCAAGCATCTG
AAACCACTGGCAAAGTTCTTGAATGATGTCAAGACCCTCTATGAGACTGAAGTCTTTTCT
ACCGACTTCTCCAACATTTCTGCAGCCAAGCAGGAGATTAACAGTCATGTGGAGATGCAA
ACCAAAGGGAAAGTTGTGGGTCTAATTCAAGACCTCAAGCCAAACACCATCATGGTCTTA
GTGAACTATATTCACTTTAAAGCCCAGTGGGCAAATCCTTTTGATCCATCCAAGACAGAA
GACAGTTCCAGCTTCTTAATAGACAAGACCACCACTGTTCAAGTGCCCATGATGCACCAG
ATGGAACAATACTATCACCTAGTGGATATGGAATTGAACTGCACAGTTCTGCAAATGGAC
TACAGCAAGAATGCTCTGGCACTCTTTGTTCTTCCCAAGGAGGGACAGATGGAGTCAGTG
GAAGCTGCCATGTCATCTAAAACACTGAAGAAGTGGAACCGCTTACTACAGAAGGGATGG
GTTGACTTGTTTGTTCCAAAGTTTTCCATTTCTGCCACATATGACCTTGGAGCCACACTT
TTGAAGATGGGCATTCAGCATGCCTATTCTGAAAATGCTGATTTTTCTGGACTCACAGAG
GACAATGGTCTGAAACTTTCCAATGCTGCCCATAAGGCTGTGCTGCACATTGGTGAAAAG
GGAACTGAAGCTGCAGCTGTCCCTGAAGTTGAACTTTCGGATCAGCCTGAAAACACTTTC
CTACACCCTATTATCCAAATTGATAGATCTTTCATGTTGTTGATTTTGGAGAGAAGCACA
AGGAGTATTCTCTTTCTAGGGAAAGTTGTGAACCCAACGGAAGCGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00079</identifier>
            <name>Serpin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>hormone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to corticosterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to peptide hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to prostaglandin E</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin A</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thyroid hormone transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
  </carriers>
  <transporters>
    <transporter position="12">
      <id>BE0003646</id>
      <name>Solute carrier family 22 member 7</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18057</ref-id>
            <pubmed-id>15901346</pubmed-id>
            <citation>Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T: Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9Y694" source="Swiss-Prot">
        <name>Solute carrier family 22 member 7</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.</specific-function>
        <gene-name>SLC22A7</gene-name>
        <locus>6p21.2-p21.1</locus>
        <cellular-location>Basolateral cell membrane</cellular-location>
        <transmembrane-regions>21-41
146-166
180-200
204-224
234-254
259-279
346-366
376-397
404-423
432-452
466-486
493-513</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.03</theoretical-pi>
        <molecular-weight>60025.025</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10971</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF097518</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>5001689</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9Y694</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A7_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOAT2</synonym>
          <synonym>NLT</synonym>
          <synonym>Novel liver transporter</synonym>
          <synonym>OAT2</synonym>
          <synonym>Organic anion transporter 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007007|Solute carrier family 22 member 7
MGFEELLEQVGGFGPFQLRNVALLALPRVLLPLHFLLPIFLAAVPAHRCALPGAPANFSH
QDVWLEAHLPREPDGTLSSCLRFAYPQALPNTTLGEERQSRGELEDEPATVPCSQGWEYD
HSEFSSTIATESQWDLVCEQKGLNRAASTFFFAGVLVGAVAFGYLSDRFGRRRLLLVAYV
STLVLGLASAASVSYVMFAITRTLTGSALAGFTIIVMPLELEWLDVEHRTVAGVLSSTFW
TGGVMLLALVGYLIRDWRWLLLAVTLPCAPGILSLWWVPESARWLLTQGHVKEAHRYLLH
CARLNGRPVCEDSFSQEAVSKVAAGERVVRRPSYLDLFRTPRLRHISLCCVVVWFGVNFS
YYGLSLDVSGLGLNVYQTQLLFGAVELPSKLLVYLSVRYAGRRLTQAGTLLGTALAFGTR
LLVSSDMKSWSTVLAVMGKAFSEAAFTTAYLFTSELYPTVLRQTGMGLTALVGRLGGSLA
PLAALLDGVWLSLPKLTYGGIALLAAGTALLLPETRQAQLPETIQDVERKSAPTSLQEEE
MPMKQVQN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012535|Solute carrier family 22 member 7 (SLC22A7)
ATGGGCTTTGAGGAGCTGCTGGAGCAGGTGGGCGGCTTTGGGCCCTTCCAACTGCGGAAT
GTGGCACTGCTGGCCCTGCCCCGAGTGCTGCTACCACTGCACTTCCTCCTGCCCATCTTC
CTGGCTGCCGTGCCTGCCCACCGATGTGCCCTGCCGGGTGCCCCTGCCAACTTCAGCCAT
CAGGATGTGTGGCTGGAGGCCCATCTTCCCCGGGAGCCTGATGGCACGCTCAGCTCCTGC
CTCCGCTTTGCCTATCCCCAGGCTCTCCCCAACACCACGTTGGGGGAAGAAAGGCAGAGC
CGTGGGGAGCTGGAGGATGAACCTGCCACAGTGCCCTGCTCTCAGGGCTGGGAGTACGAC
CACTCAGAATTCTCCTCTACCATTGCAACTGAGTGGGATCTGGTGTGTGAGCAGAAAGGT
CTGAACAGAGCTGCGTCCACTTTCTTCTTCGCCGGTGTGCTGGTGGGGGCTGTGGCCTTT
GGATATCTGTCCGACAGGTTTGGGCGGCGGCGTCTGCTGCTGGTAGCCTACGTGAGTACC
CTGGTGCTGGGCCTGGCATCTGCAGCCTCCGTCAGCTATGTAATGTTTGCCATCACCCGC
ACCCTTACTGGCTCAGCCCTGGCTGGTTTTACCATCATCGTGATGCCACTGGAGCTGGAG
TGGCTGGATGTGGAGCACCGCACCGTGGCTGGAGTCCTGAGCAGCACCTTCTGGACAGGG
GGCGTGATGCTGCTGGCACTGGTTGGGTACCTGATACGGGACTGGCGATGGCTTCTGCTA
GCTGTCACCCTGCCTTGTGCCCCAGGCATCCTCAGCCTCTGGTGGGTGCCTGAGTCTGCA
CGCTGGCTTCTGACCCAAGGCCATGTGAAAGAGGCCCACAGGTACTTGCTCCACTGTGCC
AGGCTCAATGGGCGGCCAGTGTGTGAGGACAGCTTCAGCCAGGAGGCTGTGAGCAAAGTG
GCCGCCGGGGAACGGGTGGTCCGAAGACCTTCATACCTAGACCTGTTCCGCACACCACGG
CTCCGACACATCTCACTGTGCTGCGTGGTGGTGTGGTTCGGAGTGAACTTCTCCTATTAC
GGCCTGAGTCTGGATGTGTCGGGGCTGGGGCTGAACGTGTACCAGACACAGCTGTTGTTC
GGGGCTGTGGAACTGCCCTCCAAGCTGCTGGTCTACTTGTCGGTGCGCTACGCAGGACGC
CGCCTCACGCAAGCCGGGACACTGCTGGGCACGGCCCTGGCGTTCGGCACTAGACTGCTA
GTGTCCTCCGATATGAAGTCCTGGAGCACTGTCCTGGCAGTGATGGGGAAAGCTTTTTCT
GAAGCTGCCTTCACCACTGCCTACCTGTTCACTTCAGAGTTGTACCCTACGGTGCTCAGA
CAGACAGGGATGGGGCTGACTGCACTGGTGGGCCGGCTGGGGGGCTCTTTGGCCCCACTG
GCGGCCTTGCTGGATGGAGTGTGGCTGTCACTGCCCAAGCTTACTTATGGGGGGATCGCC
CTGCTGGCTGCCGGCACCGCCCTCCTGCTGCCAGAGACGAGGCAGGCACAGCTGCCAGAG
ACCATCCAGGACGTGGAGAGAAAGAGTGCCCCAACCAGTCTTCAGGAGGAAGAGATGCCC
ATGAAGCAGGTCCAGAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07690</identifier>
            <name>MFS_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="13">
      <id>BE0001204</id>
      <name>Equilibrative nucleoside transporter 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18058</ref-id>
            <pubmed-id>17695509</pubmed-id>
            <citation>Tsujie M, Nakamori S, Nakahira S, Takahashi Y, Hayashi N, Okami J, Nagano H, Dono K, Umeshita K, Sakon M, Monden M: Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 2007 Jul-Aug;27(4B):2241-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q99808" source="Swiss-Prot">
        <name>Equilibrative nucleoside transporter 1</name>
        <general-function>Nucleoside transmembrane transporter activity</general-function>
        <specific-function>Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR) and is sodium-independent. It has a higher affinity for adenosine. Inhibited by dipyridamole and dilazep (anticancer chemotherapeutics drugs).</specific-function>
        <gene-name>SLC29A1</gene-name>
        <locus>6p21.2-p21.1</locus>
        <cellular-location>Basolateral cell membrane</cellular-location>
        <transmembrane-regions>13-29
83-107
112-130
139-157
175-199
207-227
292-311
324-342
360-378
394-413
432-452</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.39</theoretical-pi>
        <molecular-weight>50218.805</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11003</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC29A1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U81375</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1845345</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1117</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q99808</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S29A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ENT1</synonym>
          <synonym>Equilibrative NBMPR-sensitive nucleoside transporter</synonym>
          <synonym>Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter</synonym>
          <synonym>Nucleoside transporter, es-type</synonym>
          <synonym>Solute carrier family 29 member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002395|Equilibrative nucleoside transporter 1
MTTSHQPQDRYKAVWLIFFMLGLGTLLPWNFFMTATQYFTNRLDMSQNVSLVTAELSKDA
QASAAPAAPLPERNSLSAIFNNVMTLCAMLPLLLFTYLNSFLHQRIPQSVRILGSLVAIL
LVFLITAILVKVQLDALPFFVITMIKIVLINSFGAILQGSLFGLAGLLPASYTAPIMSGQ
GLAGFFASVAMICAIASGSELSESAFGYFITACAVIILTIICYLGLPRLEFYRYYQQLKL
EGPGEQETKLDLISKGEEPRAGKEESGVSVSNSQPTNESHSIKAILKNISVLAFSVCFIF
TITIGMFPAVTVEVKSSIAGSSTWERYFIPVSCFLTFNIFDWLGRSLTAVFMWPGKDSRW
LPSLVLARLVFVPLLLLCNIKPRRYLTVVFEHDAWFIFFMAAFAFSNGYLASLCMCFGPK
KVKPAEAETAGAIMAFFLCLGLALGAVFSFLFRAIV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019080|Equilibrative nucleoside transporter 1 (SLC29A1)
ATGACAACCAGTCACCAGCCTCAGGACAGATACAAAGCTGTCTGGCTTATCTTCTTCATG
CTGGGTCTGGGAACGCTGCTCCCGTGGAATTTTTTCATGACGGCCACTCAGTATTTCACA
AACCGCCTGGACATGTCCCAGAATGTGTCCTTGGTCACTGCTGAACTGAGCAAGGACGCC
CAGGCGTCAGCCGCCCCTGCAGCACCCTTGCCTGAGCGGAACTCTCTCAGTGCCATCTTC
AACAATGTCATGACCCTATGTGCCATGCTGCCCCTGCTGTTATTCACCTACCTCAACTCC
TTCCTGCATCAGAGGATCCCCCAGTCCGTACGGATCCTGGGCAGCCTGGTGGCCATCCTG
CTGGTGTTTCTGATCACTGCCATCCTGGTGAAGGTGCAGCTGGATGCTCTGCCCTTCTTT
GTCATCACCATGATCAAGATCGTGCTCATTAATTCATTTGGTGCCATCCTGCAGGGCAGC
CTGTTTGGTCTGGCTGGCCTTCTGCCTGCCAGCTACACGGCCCCCATCATGAGTGGCCAG
GGCCTAGCAGGCTTCTTTGCCTCCGTGGCCATGATCTGCGCTATTGCCAGTGGCTCGGAG
CTATCAGAAAGTGCCTTCGGCTACTTTATCACAGCCTGTGCTGTTATCATTTTGACCATC
ATCTGTTACCTGGGCCTGCCCCGCCTGGAATTCTACCGCTACTACCAGCAGCTCAAGCTT
GAAGGACCCGGGGAGCAGGAGACCAAGTTGGACCTCATTAGCAAAGGAGAGGAGCCAAGA
GCAGGCAAAGAGGAATCTGGAGTTTCAGTCTCCAACTCTCAGCCCACCAATGAAAGCCAC
TCTATCAAAGCCATCCTGAAAAATATCTCAGTCCTGGCTTTCTCTGTCTGCTTCATCTTC
ACTATCACCATTGGGATGTTTCCAGCCGTGACTGTTGAGGTCAAGTCCAGCATCGCAGGC
AGCAGCACCTGGGAACGTTACTTCATTCCTGTGTCCTGTTTCTTGACTTTCAATATCTTT
GACTGGTTGGGCCGGAGCCTCACAGCTGTATTCATGTGGCCTGGGAAGGACAGCCGCTGG
CTGCCAAGCCTGGTGCTGGCCCGGCTGGTGTTTGTGCCACTGCTGCTGCTGTGCAACATT
AAGCCCCGCCGCTACCTGACTGTGGTCTTCGAGCACGATGCCTGGTTCATCTTCTTCATG
GCTGCCTTTGCCTTCTCCAACGGCTACCTCGCCAGCCTCTGCATGTGCTTCGGGCCCAAG
AAAGTGAAGCCAGCTGAGGCAGAGACCGCAGGAGCCATCATGGCCTTCTTCCTGTGTCTG
GGTCTGGCACTGGGGGCTGTTTTCTCCTTCCTGTTCCGGGCAATTGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01733</identifier>
            <name>Nucleoside_tran</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nucleoside transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to glucose stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lactation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleoside transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleoside transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>uridine transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="14">
      <id>BE0001067</id>
      <name>ATP-binding cassette sub-family G member 2</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18059</ref-id>
            <pubmed-id>18820913</pubmed-id>
            <citation>Yuan J, Lv H, Peng B, Wang C, Yu Y, He Z: Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10. doi: 10.1007/s00280-008-0838-z. Epub 2008 Sep 27.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9UNQ0" source="Swiss-Prot">
        <name>ATP-binding cassette sub-family G member 2</name>
        <general-function>Xenobiotic-transporting atpase activity</general-function>
        <specific-function>High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. Implicated in the efflux of numerous drugs and xenobiotics: mitoxantrone, the photosensitizer pheophorbide, camptothecin, methotrexate, azidothymidine (AZT), and the anthracyclines daunorubicin and doxorubicin.</specific-function>
        <gene-name>ABCG2</gene-name>
        <locus>4q22</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>396-416
429-449
478-498
507-527
536-556
631-651</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.9</theoretical-pi>
        <molecular-weight>72313.47</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:74</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCG2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF103796</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4185796</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>792</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9UNQ0</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ABCG2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ABCP</synonym>
          <synonym>BCRP</synonym>
          <synonym>BCRP1</synonym>
          <synonym>Breast cancer resistance protein</synonym>
          <synonym>CDw338</synonym>
          <synonym>Mitoxantrone resistance-associated protein</synonym>
          <synonym>MXR</synonym>
          <synonym>Placenta-specific ATP-binding cassette transporter</synonym>
          <synonym>Urate exporter</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002125|ATP-binding cassette sub-family G member 2
MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVE
KEILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCN
SGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVIQELGLDKVADSKVGT
QFIRGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIF
SIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIING
DSTAVALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKK
ITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFGLKNDS
TGIQNRAGVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLP
MRMLPSIIFTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLL
MTICFVFMMIFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGN
NPCNYATCTGEEYLVKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016303|ATP-binding cassette sub-family G member 2 (ABCG2)
ATGTCTTCCAGTAATGTCGAAGTTTTTATCCCAGTGTCACAAGGAAACACCAATGGCTTC
CCCGCGACAGCTTCCAATGACCTGAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTCAT
AACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTTGTCGAAAACCAGTTGAG
AAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGA
CCCACAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGT
GGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGTAAT
TCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGAGAAAACTTA
CAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATCATGAAAAAAACGAACGG
ATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGGCAGACTCCAAGGTTGGAACT
CAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTAGTATAGGAATGGAGCTT
ATCACTGATCCTTCCATCTTGTTCTTGGATGAGCCTACAACTGGCTTAGACTCAAGCACA
GCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGGGACGAACAATCATCTTC
TCCATTCATCAGCCTCGATATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCC
TCAGGAAGACTTATGTTCCACGGGCCTGCTCAGGAGGCCTTGGGATACTTTGAATCAGCT
GGTTATCACTGTGAGGCCTATAATAACCCTGCAGACTTCTTCTTGGACATCATTAATGGA
GATTCCACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGAG
CCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAACTCCTCC
TTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAGAAGAAGAAGAAG
ATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGTCATCAACTCAGATGGGTT
TCCAAGCGTTCATTCAAAAACTTGCTGGGTAATCCCCAGGCCTCTATAGCTCAGATCATT
GTCACAGTCGTACTGGGACTGGTTATAGGTGCCATTTACTTTGGGCTAAAAAATGATTCT
ACTGGAATCCAGAACAGAGCTGGGGTTCTCTTCTTCCTGACGACCAACCAGTGTTTCAGC
AGTGTTTCAGCCGTGGAACTCTTTGTGGTAGAGAAGAAGCTCTTCATACATGAATACATC
AGCGGATACTACAGAGTGTCATCTTATTTCCTTGGAAAACTGTTATCTGATTTATTACCC
ATGAGGATGTTACCAAGTATTATATTTACCTGTATAGTGTACTTCATGTTAGGATTGAAG
CCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTCAGCC
AGTTCCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGTAGCAACACTTCTC
ATGACCATCTGTTTTGTGTTTATGATGGTCTGTTGGTCAATCTCACAACCATTGCATCTT
GGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATATGGATTTACGGCTTTGCAGCATA
ATGAATTTTTGGGACAAAACTTCTGCCCAGGACTCAATGCAACAGGAAACAATCCTTGTA
ACTATGCAACATGTACTGGCGAAGAATATTTGGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF01061</identifier>
            <name>ABC2_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>xenobiotic-transporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heme transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="15">
      <id>BE0001061</id>
      <name>Canalicular multispecific organic anion transporter 2</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18060</ref-id>
            <pubmed-id>19077464</pubmed-id>
            <citation>Hagmann W, Jesnowski R, Faissner R, Guo C, Lohr JM: ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44. doi: 10.1159/000178884. Epub 2008 Dec 13.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O15438" source="Swiss-Prot">
        <name>Canalicular multispecific organic anion transporter 2</name>
        <general-function>Organic anion transmembrane transporter activity</general-function>
        <specific-function>May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).</specific-function>
        <gene-name>ABCC3</gene-name>
        <locus>17q22</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>33-53
74-94
100-120
133-153
172-192
303-323
350-370
427-447
451-471
534-554
577-597
964-984
1022-1042
1086-1106
1108-1128
1200-1220
1223-1243</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.2</theoretical-pi>
        <molecular-weight>169341.14</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:54</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCC3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB010887</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3132270</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O15438</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MRP3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family C member 3</synonym>
          <synonym>CMOAT2</synonym>
          <synonym>MLP2</synonym>
          <synonym>MOAT-D</synonym>
          <synonym>MRP3</synonym>
          <synonym>Multi-specific organic anion transporter D</synonym>
          <synonym>Multidrug resistance-associated protein 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002113|Canalicular multispecific organic anion transporter 2
MDALCGSGELGSKFWDSNLSVHTENPDLTPCFQNSLLAWVPCIYLWVALPCYLLYLRHHC
RGYIILSHLSKLKMVLGVLLWCVSWADLFYSFHGLVHGRAPAPVFFVTPLVVGVTMLLAT
LLIQYERLQGVQSSGVLIIFWFLCVVCAIVPFRSKILLAKAEGEISDPFRFTTFYIHFAL
VLSALILACFREKPPFFSAKNVDPNPYPETSAGFLSRLFFWWFTKMAIYGYRHPLEEKDL
WSLKEEDRSQMVVQQLLEAWRKQEKQTARHKASAAPGKNASGEDEVLLGARPRPRKPSFL
KALLATFGSSFLISACFKLIQDLLSFINPQLLSILIRFISNPMAPSWWGFLVAGLMFLCS
MMQSLILQHYYHYIFVTGVKFRTGIMGVIYRKALVITNSVKRASTVGEIVNLMSVDAQRF
MDLAPFLNLLWSAPLQIILAIYFLWQNLGPSVLAGVAFMVLLIPLNGAVAVKMRAFQVKQ
MKLKDSRIKLMSEILNGIKVLKLYAWEPSFLKQVEGIRQGELQLLRTAAYLHTTTTFTWM
CSPFLVTLITLWVYVYVDPNNVLDAEKAFVSVSLFNILRLPLNMLPQLISNLTQASVSLK
RIQQFLSQEELDPQSVERKTISPGYAITIHSGTFTWAQDLPPTLHSLDIQVPKGALVAVV
GPVGCGKSSLVSALLGEMEKLEGKVHMKGSVAYVPQQAWIQNCTLQENVLFGKALNPKRY
QQTLEACALLADLEMLPGGDQTEIGEKGINLSGGQRQRVSLARAVYSDADIFLLDDPLSA
VDSHVAKHIFDHVIGPEGVLAGKTRVLVTHGISFLPQTDFIIVLADGQVSEMGPYPALLQ
RNGSFANFLCNYAPDEDQGHLEDSWTALEGAEDKEALLIEDTLSNHTDLTDNDPVTYVVQ
KQFMRQLSALSSDGEGQGRPVPRRHLGPSEKVQVTEAKADGALTQEEKAAIGTVELSVFW
DYAKAVGLCTTLAICLLYVGQSAAAIGANVWLSAWTNDAMADSRQNNTSLRLGVYAALGI
LQGFLVMLAAMAMAAGGIQAARVLHQALLHNKIRSPQSFFDTTPSGRILNCFSKDIYVVD
EVLAPVILMLLNSFFNAISTLVVIMASTPLFTVVILPLAVLYTLVQRFYAATSRQLKRLE
SVSRSPIYSHFSETVTGASVIRAYNRSRDFEIISDTKVDANQRSCYPYIISNRWLSIGVE
FVGNCVVLFAALFAVIGRSSLNPGLVGLSVSYSLQVTFALNWMIRMMSDLESNIVAVERV
KEYSKTETEAPWVVEGSRPPEGWPPRGEVEFRNYSVRYRPGLDLVLRDLSLHVHGGEKVG
IVGRTGAGKSSMTLCLFRILEAAKGEIRIDGLNVADIGLHDLRSQLTIIPQDPILFSGTL
RMNLDPFGSYSEEDIWWALELSHLHTFVSSQPAGLDFQCSEGGENLSVGQRQLVCLARAL
LRKSRILVLDEATAAIDLETDNLIQATIRTQFDTCTVLTIAHRLNTIMDYTRVLVLDKGV
VAEFDSPANLIAARGIFYGMARDAGLA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010744|Canalicular multispecific organic anion transporter 2 (ABCC3)
ATGGACGCCCTGTGCGGTTCCGGGGAGCTCGGCTCCAAGTTCTGGGACTCCAACCTGTCT
GTGCACACAGAAAACCCGGACCTCACTCCCTGCTTCCAGAACTCCCTGCTGGCCTGGGTG
CCCTGCATCTACCTGTGGGTCGCCCTGCCCTGCTACTTGCTCTACCTGCGGCACCATTGT
CGTGGCTACATCATCCTCTCCCACCTGTCCAAGCTCAAGATGGTCCTGGGTGTCCTGCTG
TGGTGCGTCTCCTGGGCGGACCTTTTTTACTCCTTCCATGGCCTGGTCCATGGCCGGGCC
CCTGCCCCTGTTTTCTTTGTCACCCCCTTGGTGGTGGGGGTCACCATGCTGCTGGCCACC
CTGCTGATACAGTATGAGCGGCTGCAGGGCGTACAGTCTTCGGGGGTCCTCATTATCTTC
TGGTTCCTGTGTGTGGTCTGCGCCATCGTCCCATTCCGCTCCAAGATCCTTTTAGCCAAG
GCAGAGGGTGAGATCTCAGACCCCTTCCGCTTCACCACCTTCTACATCCACTTTGCCCTG
GTACTCTCTGCCCTCATCTTGGCCTGCTTCAGGGAGAAACCTCCATTTTTCTCCGCAAAG
AATGTCGACCCTAACCCCTACCCTGAGACCAGCGCTGGCTTTCTCTCCCGCCTGTTTTTC
TGGTGGTTCACAAAGATGGCCATCTATGGCTACCGGCATCCCCTGGAGGAGAAGGACCTC
TGGTCCCTAAAGGAAGAGGACAGATCCCAGATGGTGGTGCAGCAGCTGCTGGAGGCATGG
AGGAAGCAGGAAAAGCAGACGGCACGACACAAGGCTTCAGCAGCACCTGGGAAAAATGCC
TCCGGCGAGGACGAGGTGCTGCTGGGTGCCCGGCCCAGGCCCCGGAAGCCCTCCTTCCTG
AAGGCCCTGCTGGCCACCTTCGGCTCCAGCTTCCTCATCAGTGCCTGCTTCAAGCTTATC
CAGGACCTGCTCTCCTTCATCAATCCACAGCTGCTCAGCATCCTGATCAGGTTTATCTCC
AACCCCATGGCCCCCTCCTGGTGGGGCTTCCTGGTGGCTGGGCTGATGTTCCTGTGCTCC
ATGATGCAGTCGCTGATCTTACAACACTATTACCACTACATCTTTGTGACTGGGGTGAAG
TTTCGTACTGGGATCATGGGTGTCATCTACAGGAAGGCTCTGGTTATCACCAACTCAGTC
AAACGTGCGTCCACTGTGGGGGAAATTGTCAACCTCATGTCAGTGGATGCCCAGCGCTTC
ATGGACCTTGCCCCCTTCCTCAATCTGCTGTGGTCAGCACCCCTGCAGATCATCCTGGCG
ATCTACTTCCTCTGGCAGAACCTAGGTCCCTCTGTCCTGGCTGGAGTCGCTTTCATGGTC
TTGCTGATTCCACTCAACGGAGCTGTGGCCGTGAAGATGCGCGCCTTCCAGGTAAAGCAA
ATGAAATTGAAGGACTCGCGCATCAAGCTGATGAGTGAGATCCTGAACGGCATCAAGGTG
CTGAAGCTGTACGCCTGGGAGCCCAGCTTCCTGAAGCAGGTGGAGGGCATCAGGCAGGGT
GAGCTCCAGCTGCTGCGCACGGCGGCCTACCTCCACACCACAACCACCTTCACCTGGATG
TGCAGCCCCTTCCTGGTGAGGCTTGGCACAGGGCTGGGTCCCTGCCTCCAGGGCTCTGGG
TGCCCAGGCATGGCCAGGGCTCATTGGACTCTACCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="16">
      <id>BE0001188</id>
      <name>Multidrug resistance-associated protein 4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18060</ref-id>
            <pubmed-id>19077464</pubmed-id>
            <citation>Hagmann W, Jesnowski R, Faissner R, Guo C, Lohr JM: ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44. doi: 10.1159/000178884. Epub 2008 Dec 13.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O15439" source="Swiss-Prot">
        <name>Multidrug resistance-associated protein 4</name>
        <general-function>Atpase activity, coupled to transmembrane movement of substances</general-function>
        <specific-function>May be an organic anion pump relevant to cellular detoxification.</specific-function>
        <gene-name>ABCC4</gene-name>
        <locus>13q32</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>93-113
136-156
207-227
228-248
328-348
351-371
440-460
710-730
771-791
836-856
858-878
954-974
977-997
1038-1058</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.39</theoretical-pi>
        <molecular-weight>149525.33</molecular-weight>
        <chromosome-location>13</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:55</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCC4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF071202</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3335173</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>782</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O15439</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MRP4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family C member 4</synonym>
          <synonym>MOAT-B</synonym>
          <synonym>MRP/cMOAT-related ABC transporter</synonym>
          <synonym>MRP4</synonym>
          <synonym>Multi-specific organic anion transporter B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037136|Multidrug resistance-associated protein 4
MLPVYQEVKPNPLQDANLCSRVFFWWLNPLFKIGHKRRLEEDDMYSVLPEDRSQHLGEEL
QGFWDKEVLRAENDAQKPSLTRAIIKCYWKSYLVLGIFTLIEESAKVIQPIFLGKIINYF
ENYDPMDSVALNTAYAYATVLTFCTLILAILHHLYFYHVQCAGMRLRVAMCHMIYRKALR
LSNMAMGKTTTGQIVNLLSNDVNKFDQVTVFLHFLWAGPLQAIAVTALLWMEIGISCLAG
MAVLIILLPLQSCFGKLFSSLRSKTATFTDARIRTMNEVITGIRIIKMYAWEKSFSNLIT
NLRKKEISKILRSSCLRGMNLASFFSASKIIVFVTFTTYVLLGSVITASRVFVAVTLYGA
VRLTVTLFFPSAIERVSEAIVSIRRIQTFLLLDEISQRNRQLPSDGKKMVHVQDFTAFWD
KASETPTLQGLSFTVRPGELLAVVGPVGAGKSSLLSAVLGELAPSHGLVSVHGRIAYVSQ
QPWVFSGTLRSNILFGKKYEKERYEKVIKACALKKDLQLLEDGDLTVIGDRGTTLSGGQK
ARVNLARAVYQDADIYLLDDPLSAVDAEVSRHLFELCICQILHEKITILVTHQLQYLKAA
SQILILKDGKMVQKGTYTEFLKSGIDFGSLLKKDNEESEQPPVPGTPTLRNRTFSESSVW
SQQSSRPSLKDGALESQDTENVPVTLSEENRSEGKVGFQAYKNYFRAGAHWIVFIFLILL
NTAAQVAYVLQDWWLSYWANKQSMLNVTVNGGGNVTEKLDLNWYLGIYSGLTVATVLFGI
ARSLLVFYVLVNSSQTLHNKMFESILKAPVLFFDRNPIGRILNRFSKDIGHLDDLLPLTF
LDFIQTLLQVVGVVSVAVAVIPWIAIPLVPLGIIFIFLRRYFLETSRDVKRLESTTRSPV
FSHLSSSLQGLWTIRAYKAEERCQELFDAHQDLHSEAWFLFLTTSRWFAVRLDAICAMFV
IIVAFGSLILAKTLDAGQVGLALSYALTLMGMFQWCVRQSAEVENMMISVERVIEYTDLE
KEAPWEYQKRPPPAWPHEGVIIFDNVNFMYSPGGPLVLKHLTALIKSQEKVGIVGRTGAG
KSSLISALFRLSEPEGKIWIDKILTTEIGLHDLRKKMSIIPQEPVLFTGTMRKNLDPFNE
HTDEELWNALQEVQLKETIEDLPGKMDTELAESGSNFSVGQRQLVCLARAILRKNQILII
DEATANVDPRTDELIQKKIREKFAHCTVLTIAHRLNTIIDSDKIMVLDSGRLKEYDEPYV
LLQNKESLFYKMVQQLGKAEAAALTETAKQVYFKRNYPHIGHTDHMVTNTSNGQPSTLTI
FETAL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010828|Multidrug resistance-associated protein 4 (ABCC4)
ATGCTGCCCGTGTACCAGGAGGTGAAGCCCAACCCGCTGCAGGACGCGAACCTCTGCTCA
CGCGTGTTCTTCTGGTGGCTCAATCCCTTGTTTAAAATTGGCCATAAACGGAGATTAGAG
GAAGATGATATGTATTCAGTGCTGCCAGAAGACCGCTCACAGCACCTTGGAGAGGAGTTG
CAAGGGTTCTGGGATAAAGAAGTTTTAAGAGCTGAGAATGACGCACAGAAGCCTTCTTTA
ACAAGAGCAATCATAAAGTGTTACTGGAAATCTTATTTAGTTTTGGGAATTTTTACGTTA
ATTGAGGAAAGTGCCAAAGTAATCCAGCCCATATTTTTGGGAAAAATTATTAATTATTTT
GAAAATTATGATCCCATGGATTCTGTGGCTTTGAACACAGCGTACGCCTATGCCACGGTG
CTGACTTTTTGCACGCTCATTTTGGCTATACTGCATCACTTATATTTTTATCACGTTCAG
TGTGCTGGGATGAGGTTACGAGTAGCCATGTGCCATATGATTTATCGGAAGGCACTTCGT
CTTAGTAACATGGCCATGGGGAAGACAACCACAGGCCAGATAGTCAATCTGCTGTCCAAT
GATGTGAACAAGTTTGATCAGGTGACAGTGTTCTTACACTTCCTGTGGGCAGGACCACTG
CAGGCGATTGCAGTGACTGCCCTACTCTGGATGGAGATAGGAATATCGTGCCTTGCTGGG
ATGGCAGTTCTAATCATTCTCCTGCCCTTGCAAAGCTGTTTTGGGAAGTTGTTCTCATCA
CTGAGGAGTAAAACTGCAACTTTCACGGATGCCAGGATCAGGACCATGAATGAAGTTATA
ACTGGTATAAGGATAATAAAAATGTACGCCTGGGAAAAGTCATTTTCAAATCTTATTACC
AATTTGAGAAAGAAGGAGATTTCCAAGATTCTGAGAAGTTCCTGCCTCAGAGGGATGAAT
TTGGCTTCATTTTTCAGTGCAAGCAAAATCATCGTGTTTGTGACCTTCACCACCTACGTG
CTCCTCGGCAGTGTGATCACAGCCAGCCGCGTGTTCGTGGCAGTGACGCTGTATGGGGCT
GTGCGGCTGACGGTTACCCTCTTCTTCCCCTCAGCCATTGAGAGGGTGTCAGAGGCAATC
GTCAGCATCCGAAGAATCCAGACCTTTTTGCTACTTGATGAGATATCACAGCGCAACCGT
CAGCTGCCGTCAGATGGTAAAAAGATGGTGCATGTGCAGGATTTTACTGCTTTTTGGGAT
AAGGCATCAGAGACCCCAACTCTACAAGGCCTTTCCTTTACTGTCAGACCTGGCGAATTG
TTAGCTGTGGTCGGCCCCGTGGGAGCAGGGAAGTCATCACTGTTAAGTGCCGTGCTCGGG
GAATTGGCCCCAAGTCACGGGCTGGTCAGCGTGCATGGAAGAATTGCCTATGTGTCTCAG
CAGCCCTGGGTGTTCTCGGGAACTCTGAGGAGTAATATTTTATTTGGGAAGAAATACGAA
AAGGAACGATATGAAAAAGTCATAAAGGCTTGTGCTCTGAAAAAGGATTTACAGCTGTTG
GAGGATGGTGATCTGACTGTGATAGGAGATCGGGGAACCACGCTGAGTGGAGGGCAGAAA
GCACGGGTAAACCTTGCAAGAGCAGTGTATCAAGATGCTGACATCTATCTCCTGGACGAT
CCTCTCAGTGCAGTAGATGCGGAAGTTAGCAGACACTTGTTCGAACTGTGTATTTGTCAA
ATTTTGCATGAGAAGATCACAATTTTAGTGACTCATCAGTTGCAGTACCTCAAAGCTGCA
AGTCAGATTCTGATATTGAAAGATGGTAAAATGGTGCAGAAGGGGACTTACACTGAGTTC
CTAAAATCTGGTATAGATTTTGGCTCCCTTTTAAAGAAGGATAATGAGGAAAGTGAACAA
CCTCCAGTTCCAGGAACTCCCACACTAAGGAATCGTACCTTCTCAGAGTCTTCGGTTTGG
TCTCAACAATCTTCTAGACCCTCCTTGAAAGATGGTGCTCTGGAGAGCCAAGATACAGAG
AATGTCCCAGTTACACTATCAGAGGAGAACCGTTCTGAAGGAAAAGTTGGTTTTCAGGCC
TATAAGAATTACTTCAGAGCTGGTGCTCACTGGATTGTCTTCATTTTCCTTATTCTCCTA
AACACTGCAGCTCAGGTTGCCTATGTGCTTCAAGATTGGTGGCTTTCATACTGGGCAAAC
AAACAAAGTATGCTAAATGTCACTGTAAATGGAGGAGGAAATGTAACCGAGAAGCTAGAT
CTTAACTGGTACTTAGGAATTTATTCAGGTTTAACTGTAGCTACCGTTCTTTTTGGCATA
GCAAGATCTCTATTGGTATTCTACGTCCTTGTTAACTCTTCACAAACTTTGCACAACAAA
ATGTTTGAGTCAATTCTGAAAGCTCCGGTATTATTCTTTGATAGAAATCCAATAGGAAGA
ATTTTAAATCGTTTCTCCAAAGACATTGGACACTTGGATGATTTGCTGCCGCTGACGTTT
TTAGATTTCATCCAGAGATGGGATCTCGCTGTGTTGTCCTGGCTGGTCTCAAACTCCTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet dense granule membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>15-hydroxyprostaglandin dehydrogenase (NAD+) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="17">
      <id>BE0003639</id>
      <name>Multidrug resistance-associated protein 5</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A18060</ref-id>
            <pubmed-id>19077464</pubmed-id>
            <citation>Hagmann W, Jesnowski R, Faissner R, Guo C, Lohr JM: ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44. doi: 10.1159/000178884. Epub 2008 Dec 13.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O15440" source="Swiss-Prot">
        <name>Multidrug resistance-associated protein 5</name>
        <general-function>Organic anion transmembrane transporter activity</general-function>
        <specific-function>Acts as a multispecific organic anion pump which can transport nucleotide analogs.</specific-function>
        <gene-name>ABCC5</gene-name>
        <locus>3q27</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>179-199
219-239
296-316
317-337
400-420
434-454
608-628
848-868
917-937
997-1017
1018-1038
1104-1124
1127-1147</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.89</theoretical-pi>
        <molecular-weight>160658.8</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:56</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF104942</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4140698</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>783</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O15440</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MRP5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATP-binding cassette sub-family C member 5</synonym>
          <synonym>MOAT-C</synonym>
          <synonym>MRP5</synonym>
          <synonym>Multi-specific organic anion transporter C</synonym>
          <synonym>pABC11</synonym>
          <synonym>SMRP</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006995|Multidrug resistance-associated protein 5
MKDIDIGKEYIIPSPGYRSVRERTSTSGTHRDREDSKFRRTRPLECQDALETAARAEGLS
LDASMHSQLRILDEEHPKGKYHHGLSALKPIRTTSKHQHPVDNAGLFSCMTFSWLSSLAR
VAHKKGELSMEDVWSLSKHESSDVNCRRLERLWQEELNEVGPDAASLRRVVWIFCRTRLI
LSIVCLMITQLAGFSGPAFMVKHLLEYTQATESNLQYSLLLVLGLLLTEIVRSWSLALTW
ALNYRTGVRLRGAILTMAFKKILKLKNIKEKSLGELINICSNDGQRMFEAAAVGSLLAGG
PVVAILGMIYNVIILGPTGFLGSAVFILFYPAMMFASRLTAYFRRKCVAATDERVQKMNE
VLTYIKFIKMYAWVKAFSQSVQKIREEERRILEKAGYFQSITVGVAPIVVVIASVVTFSV
HMTLGFDLTAAQAFTVVTVFNSMTFALKVTPFSVKSLSEASVAVDRFKSLFLMEEVHMIK
NKPASPHIKIEMKNATLAWDSSHSSIQNSPKLTPKMKKDKRASRGKKEKVRQLQRTEHQA
VLAEQKGHLLLDSDERPSPEEEEGKHIHLGHLRLQRTLHSIDLEIQEGKLVGICGSVGSG
KTSLISAILGQMTLLEGSIAISGTFAYVAQQAWILNATLRDNILFGKEYDEERYNSVLNS
CCLRPDLAILPSSDLTEIGERGANLSGGQRQRISLARALYSDRSIYILDDPLSALDAHVG
NHIFNSAIRKHLKSKTVLFVTHQLQYLVDCDEVIFMKEGCITERGTHEELMNLNGDYATI
FNNLLLGETPPVEINSKKETSGSQKKSQDKGPKTGSVKKEKAVKPEEGQLVQLEEKGQGS
VPWSVYGVYIQAAGGPLAFLVIMALFMLNVGSTAFSTWWLSYWIKQGSGNTTVTRGNETS
VSDSMKDNPHMQYYASIYALSMAVMLILKAIRGVVFVKGTLRASSRLHDELFRRILRSPM
KFFDTTPTGRILNRFSKDMDEVDVRLPFQAEMFIQNVILVFFCVGMIAGVFPWFLVAVGP
LVILFSVLHIVSRVLIRELKRLDNITQSPFLSHITSSIQGLATIHAYNKGQEFLHRYQEL
LDDNQAPFFLFTCAMRWLAVRLDLISIALITTTGLMIVLMHGQIPPAYAGLAISYAVQLT
GLFQFTVRLASETEARFTSVERINHYIKTLSLEAPARIKNKAPSPDWPQEGEVTFENAEM
RYRENLPLVLKKVSFTIKPKEKIGIVGRTGSGKSSLGMALFRLVELSGGCIKIDGVRISD
IGLADLRSKLSIIPQEPVLFSGTVRSNLDPFNQYTEDQIWDALERTHMKECIAQLPLKLE
SEVMENGDNFSVGERQLLCIARALLRHCKILILDEATAAMDTETDLLIQETIREAFADCT
MLTIAHRLHTVLGSDRIMVLAQGQVVEFDTPSVLLSNDSSRFYAMFAAAENKVAVKG</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012531|Multidrug resistance-associated protein 5 (ABCC5)
ATGAAGGATATCGACATAGGAAAAGAGTATATCATCCCCAGTCCTGGGTATAGAAGTGTG
AGGGAGAGAACCAGCACTTCTGGGACGCACAGAGACCGTGAAGATTCCAAGTTCAGGAGA
ACTCGACCGTTGGAATGCCAAGATGCCTTGGAAACAGCAGCCCGAGCCGAGGGCCTCTCT
CTTGATGCCTCCATGCATTCTCAGCTCAGAATCCTGGATGAGGAGCATCCCAAGGGAAAG
TACCATCATGGCTTGAGTGCTCTGAAGCCCATCCGGACTACTTCCAAACACCAGCACCCA
GTGGACAATGCTGGGCTTTTTTCCTGTATGACTTTTTCGTGGCTTTCTTCTCTGGCCCGT
GTGGCCCACAAGAAGGGGGAGCTCTCAATGGAAGACGTGTGGTCTCTGTCCAAGCACGAG
TCTTCTGACGTGAACTGCAGAAGACTAGAGAGACTGTGGCAAGAAGAGCTGAATGAAGTT
GGGCCAGACGCTGCTTCCCTGCGAAGGGTTGTGTGGATCTTCTGCCGCACCAGGCTCATC
CTGTCCATCGTGTGCCTGATGATCACGCAGCTGGCTGGCTTCAGTGGACCAAATTTTCAG
GATGGCTGTATTCTGCGGTCAGAATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carbohydrate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycosaminoglycan metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hyaluronan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hyaluronan metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>